memantine has been researched along with Disease Models, Animal in 241 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Memantine, 30 mg/kg per day, or vehicle, was delivered chronically in drinking water beginning >2 hours after photothrombotic stroke." | 9.19 | Memantine enhances recovery from stroke. ( Ao, Y; Brennan, KC; Carmichael, ST; Charles, AC; Clarkson, AN; López-Valdés, HE; Sofroniew, MV, 2014) |
| "we made animal models in the natural environment of the Qinghai-Tibet Plateau at an altitude of 4300 m, and used animal behavior, morphology, molecular biology and other methods to evaluate the impact of chronic hypoxia exposure on cognitive function and the neuroprotective effect of Memantine." | 8.02 | Memantine ameliorates cognitive impairment induced by exposure to chronic hypoxia environment at high altitude by inhibiting excitotoxicity. ( Ge, RL; Ji, W; Liu, J; Luo, J; Wan, Y; Zhang, Y, 2021) |
| "Chronic quinpirole (QNP) sensitization is an established animal model relevant to obsessive-compulsive disorder (OCD) that has been previously shown to induce several OCD-like behavioral patterns, such as compulsive-like checking and increased locomotion." | 7.91 | No effect of riluzole and memantine on learning deficit following quinpirole sensitization - An animal model of obsessive-compulsive disorder. ( Brozka, H; Janikova, M; Radostova, D; Stuchlik, A; Svoboda, J, 2019) |
| "Several studies have reported on the beneficial effects of memantine on behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease." | 7.91 | Memantine ameliorates learning and memory disturbance and the behavioral and psychological symptoms of dementia in thiamine-deficient mice. ( Kashimoto, Y; Kitano, Y; Makino, M; Murasawa, H; Pawlak, A; Takahashi-Ito, K, 2019) |
| "The purpose of this study was to investigate the effects of memantine on brain ischemia." | 7.88 | Effects of Memantine on Nitric Oxide Production and Hydroxyl Radical Metabolism during Cerebral Ischemia and Reperfusion in Mice. ( Araki, N; Hirayama, M; Ishizawa, K; Ito, Y; Kawasaki, H; Kitabayashi, C; Nagai, T; Nishioka, R; Takahashi, K; Tanaka, A; Yamamoto, T; Yamazato, M, 2018) |
| "7-day old rats were subjected to hypoxia-ischemia (H-I) and treated with combination of memantine and HBO or HH." | 7.83 | Combining hypobaric hypoxia or hyperbaric oxygen postconditioning with memantine reduces neuroprotection in 7-day-old rat hypoxia-ischemia. ( Bratek, E; Gamdzyk, M; Salinska, E; Ziembowicz, A, 2016) |
| "Riluzole and memantine can be safely and effectively delivered intracranially via polymer in rat glioma models." | 7.80 | Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models. ( Blakeley, J; Brem, H; Gincel, D; Pardo, AC; Rothstein, JD; Tyler, B; Weaver, KD; Yohay, K, 2014) |
| "We investigated a possible drug efficacy enhancement obtained by combining inactive doses of galantamine and memantine in the scopolamine-induced amnesia model in mice." | 7.78 | Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice. ( Bertorelli, R; Busquet, P; Capurro, V; Cavalli, A; Piomelli, D; Reggiani, A, 2012) |
| "This study applies treatment methods to rat retinas subjected to acute ischemia reperfusion injury and compares the efficacy of memantine, hyperbaric oxygen (HBO) therapy, and brimonidine by histopathological examination." | 7.77 | An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury. ( Aktaş, S; Cağatay, H; Cumbul, A; Erdenöz, S; Eskicoğlu, E; Oba, E; Uslu, U; Yiğit, U, 2011) |
| " Furthermore, we evaluated the effect of anti-dementia drugs memantine, a NMDA antagonist, and donepezil, a cholinesterase inhibitor, on OKA ICV induced memory impairment." | 7.76 | Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. ( Kamat, PK; Nath, C; Saxena, G; Shukla, R; Tota, S, 2010) |
| "Memantine, a N-methyl-D-aspartate (NMDA) receptor antagonist, inhibits hematoma expansion and celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces perihematomal inflammation in intracerebral hemorrhage." | 7.74 | Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage. ( Chu, K; Jung, KH; Kim, JM; Kim, M; Lee, ST; Park, DK; Roh, JK; Sinn, DI; Song, EC, 2007) |
| "We conclude from our experiments that add-on therapy with memantine did not alter the effect of thrombolysis in an embolic stroke model." | 7.74 | Failure to improve the effect of thrombolysis by memantine in a rat embolic stroke model. ( Back, T; Hennerici, MG; Kittner, D; Mennel, HD; Otto, D; Schüler, OG, 2007) |
| "The finding that memantine protects adult visual neurons from transsynaptic atrophy in experimental glaucoma could have therapeutic value." | 7.73 | Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. ( Gupta, N; Kalichman, MW; Mizisin, AP; Weinreb, RN; Yücel, YH; Zhang, Q, 2006) |
| "Combinations of memantine with clenbuterol extend the respective therapeutic window and provide synergistic cerebroprotective effects after stroke." | 7.72 | Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol. ( Culmsee, C; Junker, V; Kremers, W; Krieglstein, J; Plesnila, N; Thal, S, 2004) |
| "To determine, using electrophysiological measures of visual system function, whether oral daily dosing of memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 7.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. ( Chun, T; Hare, WA; Lai, RK; Ruiz, G; Ton, H; Wheeler, L; WoldeMussie, E, 2004) |
| "To determine, using anatomic measurements, whether daily oral dosing with memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 7.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. ( Feldmann, B; Hare, WA; Ruiz, G; Ton, H; Weinreb, RN; Wheeler, L; Wijono, M; WoldeMussie, E; Zangwill, L, 2004) |
| "Retinal ischemia increased vitreous concentrations of glutamate and glycine." | 7.70 | Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. ( Bach, M; Feuerstein, TJ; Knörle, R; Lagrèze, WA, 1998) |
| "Seizures were evaluated by video-EEG during one hour and scored according to Racine scale." | 5.62 | Effect of Memantine on Pentylenetetrazol-induced Seizures and EEG Profile in Animal Model of Cortical Malformation. ( Cagliari Zenki, K; Calcagnotto, ME; Klippel Zanona, Q; Lazzarotto, G, 2021) |
| "Memantine has demonstrated beneficial effects on several types of brain insults via therapeutic mechanisms mainly related to its activity as a receptor antagonist of N-methyl-d-aspartate." | 5.62 | Memantine protects blood-brain barrier integrity and attenuates neurological deficits through inhibiting nitric oxide synthase ser1412 phosphorylation in intracerebral hemorrhage rats: involvement of peroxynitrite-related matrix metalloproteinase-9/NLRP3 ( Chen, M; Chen, X; Chen, Z; Gao, Z; Huang, H; Mou, Y; Song, M; Xiang, X; Xie, T; Xie, X, 2021) |
| " This was not observed when memantine treatment was combined with vitamin D enrichment." | 5.62 | Effect of Memantine Treatment and Combination with Vitamin D Supplementation on Body Composition in the APP/PS1 Mouse Model of Alzheimer's Disease Following Chronic Vitamin D Deficiency. ( Annweiler, C; Bartha, R; Beauchet, O; Bellyou, M; Broberg, DN; Doad, J; Holdsworth, DW; Montero-Odasso, M; Norley, CJD; Umoh, JU; Wong, D, 2021) |
| "Memantine (Mem) is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist used in the treatment of Alzheimer's disease." | 5.62 | [Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment]. ( Aoki, Y; Han, LK; Kaneda, M; Michihara, S; Shimoyama, T; Takahashi, R, 2021) |
| "Memantine was administered by oral gavage." | 5.56 | Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders. ( Chan, KH; Kwan, JS; Ma, OK; Tang, CH; Yick, LW, 2020) |
| "Alcoholism is a chronic relapsing disorder with consequences on health and that requires more effective treatments." | 5.42 | Memantine reduces alcohol drinking but not relapse in alcohol-dependent rats. ( Alaux-Cantin, S; Buttolo, R; Houchi, H; Jeanblanc, J; Naassila, M, 2015) |
| "Delayed cerebral vasospasm is an important pathological feature of subarachnoid hemorrhage (SAH)." | 5.42 | Memantine Attenuates Delayed Vasospasm after Experimental Subarachnoid Hemorrhage via Modulating Endothelial Nitric Oxide Synthase. ( Huang, CY; Pan, CH; Shan, YS; Tsai, KJ; Wang, LC, 2015) |
| "As dementia and depression are co-morbid, we evaluated if this combination would have an effect on cognition." | 5.40 | Role of glutamate and advantages of combining memantine with a 5HT6 ligand in a model of depression. ( Abraham, R; Nirogi, R; Shinde, A, 2014) |
| "Memantine treatment of Fmr1-KO CGCs promoted cell adhesion properties." | 5.38 | The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. ( Brown, WT; Dobkin, C; Li, X; Malik, M; Sheikh, AM; Wei, H, 2012) |
| "Memantine treatment improved spatial and recognition memory performance in the Ts65Dn mice, though not to the level of normosomic littermate controls." | 5.37 | Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. ( Bimonte-Nelson, H; Boger, H; Granholm, AC; Lockrow, J, 2011) |
| "The mechanism of cerebral hypoxia-induced myoclonic jerks is not known." | 5.36 | Memantine exacerbates myoclonic jerks in a rat model of posthypoxic myoclonus. ( Tai, KK; Truong, DD, 2010) |
| "Intracerebral hemorrhage was induced via the infusion of collagenase into the left basal ganglia of adult rats." | 5.33 | Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement. ( Chu, K; Jung, KH; Kim, EH; Kim, J; Kim, M; Kim, SJ; Ko, SY; Lee, ST; Roh, JK; Sinn, DI, 2006) |
| "Memantine treatment significantly delayed the disease progression and increased the life span of SOD1(G93A) mice, from 121." | 5.33 | Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. ( Wang, R; Zhang, D, 2005) |
| "Pretreatment with risperidone (0." | 5.32 | Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2004) |
| "Memantine, 30 mg/kg per day, or vehicle, was delivered chronically in drinking water beginning >2 hours after photothrombotic stroke." | 5.19 | Memantine enhances recovery from stroke. ( Ao, Y; Brennan, KC; Carmichael, ST; Charles, AC; Clarkson, AN; López-Valdés, HE; Sofroniew, MV, 2014) |
| " The cholinesterase inhibitor rivastigmine and the NMDA receptor antagonist memantine were used to investigate the effects of drugs, used to treat AD cognitive dysfunction, on breathing in hypoxia and hypercapnia." | 4.12 | Hypoxic and Hypercapnic Responses in Transgenic Murine Model of Alzheimer's Disease Overexpressing Human AβPP: The Effects of Pretreatment with Memantine and Rivastigmine. ( Andrzejewski, K; Conde, SV; Jampolska, M; Kaczyńska, K; Mojzych, I, 2022) |
| "Memantine can promote the survival of skin flap in rats by improving the blood supply, promoting angiogenesis, inhibiting the inflammatory response, and reducing ischemia-reperfusion injury." | 4.02 | Effect of memantine on the survival of an ischemic random skin flap and the underlying mechanism. ( Chen, J; Chen, T; Fan, W; Li, Z; Lin, D; Liu, S; Liu, Z, 2021) |
| "To investigate the potential antitumor effect of memantine by reducing glutamate levels in 4T1 mouse breast cancer model." | 4.02 | Antitumorigenic Effect of Memantine via Interfering Glutamate Metabolism in Mouse 4T1 Breast Tumor Model. ( Albayrak, G; Bagriacik, EU; Bali, EB; Korkmaz, FD, 2021) |
| "we made animal models in the natural environment of the Qinghai-Tibet Plateau at an altitude of 4300 m, and used animal behavior, morphology, molecular biology and other methods to evaluate the impact of chronic hypoxia exposure on cognitive function and the neuroprotective effect of Memantine." | 4.02 | Memantine ameliorates cognitive impairment induced by exposure to chronic hypoxia environment at high altitude by inhibiting excitotoxicity. ( Ge, RL; Ji, W; Liu, J; Luo, J; Wan, Y; Zhang, Y, 2021) |
| "Chronic quinpirole (QNP) sensitization is an established animal model relevant to obsessive-compulsive disorder (OCD) that has been previously shown to induce several OCD-like behavioral patterns, such as compulsive-like checking and increased locomotion." | 3.91 | No effect of riluzole and memantine on learning deficit following quinpirole sensitization - An animal model of obsessive-compulsive disorder. ( Brozka, H; Janikova, M; Radostova, D; Stuchlik, A; Svoboda, J, 2019) |
| "Several studies have reported on the beneficial effects of memantine on behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease." | 3.91 | Memantine ameliorates learning and memory disturbance and the behavioral and psychological symptoms of dementia in thiamine-deficient mice. ( Kashimoto, Y; Kitano, Y; Makino, M; Murasawa, H; Pawlak, A; Takahashi-Ito, K, 2019) |
| "The purpose of this study was to investigate the effects of memantine on brain ischemia." | 3.88 | Effects of Memantine on Nitric Oxide Production and Hydroxyl Radical Metabolism during Cerebral Ischemia and Reperfusion in Mice. ( Araki, N; Hirayama, M; Ishizawa, K; Ito, Y; Kawasaki, H; Kitabayashi, C; Nagai, T; Nishioka, R; Takahashi, K; Tanaka, A; Yamamoto, T; Yamazato, M, 2018) |
| " We hypothesized that hyper-excitability in Huntington disease (HD) disrupts the coordinated structural and functional connectivity, and treatment with memantine helps to reduce excitotoxicity and normalize the connectivity." | 3.88 | Connectomic imaging reveals Huntington-related pathological and pharmaceutical effects in a mouse model. ( Chang, WT; Chuang, KH; Garcia-Miralles, M; Koh, KB; Pouladi, MA; Puspitasari, F; Tan, LJ; Tay, HC; Yeow, LY, 2018) |
| "7-day old rats were subjected to hypoxia-ischemia (H-I) and treated with combination of memantine and HBO or HH." | 3.83 | Combining hypobaric hypoxia or hyperbaric oxygen postconditioning with memantine reduces neuroprotection in 7-day-old rat hypoxia-ischemia. ( Bratek, E; Gamdzyk, M; Salinska, E; Ziembowicz, A, 2016) |
| " Memantine significantly mitigated the oxidative stress, lung inflammatory response and acute lung injury caused by BLM." | 3.81 | NMDA Receptor Antagonist Attenuates Bleomycin-Induced Acute Lung Injury. ( Cheng, Q; Feng, D; Han, J; Huang, X; Huang, Y; Li, L; Li, Y; Liu, W; Liu, Y; Luo, S; Luo, Z; Peng, X; Yue, SJ; Zhao, F, 2015) |
| "Riluzole and memantine can be safely and effectively delivered intracranially via polymer in rat glioma models." | 3.80 | Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models. ( Blakeley, J; Brem, H; Gincel, D; Pardo, AC; Rothstein, JD; Tyler, B; Weaver, KD; Yohay, K, 2014) |
| "We investigated a possible drug efficacy enhancement obtained by combining inactive doses of galantamine and memantine in the scopolamine-induced amnesia model in mice." | 3.78 | Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice. ( Bertorelli, R; Busquet, P; Capurro, V; Cavalli, A; Piomelli, D; Reggiani, A, 2012) |
| "This study applies treatment methods to rat retinas subjected to acute ischemia reperfusion injury and compares the efficacy of memantine, hyperbaric oxygen (HBO) therapy, and brimonidine by histopathological examination." | 3.77 | An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury. ( Aktaş, S; Cağatay, H; Cumbul, A; Erdenöz, S; Eskicoğlu, E; Oba, E; Uslu, U; Yiğit, U, 2011) |
| " Furthermore, we evaluated the effect of anti-dementia drugs memantine, a NMDA antagonist, and donepezil, a cholinesterase inhibitor, on OKA ICV induced memory impairment." | 3.76 | Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. ( Kamat, PK; Nath, C; Saxena, G; Shukla, R; Tota, S, 2010) |
| "Memantine, a N-methyl-D-aspartate (NMDA) receptor antagonist, inhibits hematoma expansion and celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces perihematomal inflammation in intracerebral hemorrhage." | 3.74 | Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage. ( Chu, K; Jung, KH; Kim, JM; Kim, M; Lee, ST; Park, DK; Roh, JK; Sinn, DI; Song, EC, 2007) |
| "We conclude from our experiments that add-on therapy with memantine did not alter the effect of thrombolysis in an embolic stroke model." | 3.74 | Failure to improve the effect of thrombolysis by memantine in a rat embolic stroke model. ( Back, T; Hennerici, MG; Kittner, D; Mennel, HD; Otto, D; Schüler, OG, 2007) |
| " The three models were benchmarked using compounds known to be active in neuropathic pain patients and nerve injury animal models, including gabapentin, amitriptyline and clonidine." | 3.74 | Transient allodynia pain models in mice for early assessment of analgesic activity. ( Cheevers, CV; Donello, JE; Gil, DW, 2008) |
| "This study investigated the involvement of the L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) pathway in the antidepressant-like effect of an acute administration of memantine in the forced swimming test (FST) in mice, since this signaling pathway is supposed to play a significant role in depression." | 3.73 | Evidence for the involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice. ( Almeida, RC; Felisbino, CS; Gabilan, NH; López, MG; Rodrigues, AL, 2006) |
| "The finding that memantine protects adult visual neurons from transsynaptic atrophy in experimental glaucoma could have therapeutic value." | 3.73 | Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. ( Gupta, N; Kalichman, MW; Mizisin, AP; Weinreb, RN; Yücel, YH; Zhang, Q, 2006) |
| "Combinations of memantine with clenbuterol extend the respective therapeutic window and provide synergistic cerebroprotective effects after stroke." | 3.72 | Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol. ( Culmsee, C; Junker, V; Kremers, W; Krieglstein, J; Plesnila, N; Thal, S, 2004) |
| "A series of mutual prodrugs derived from gabapentin, pregabalin, memantine, venlafaxine were synthesized and their pharmacological properties to treat neuropathic pain were investigated in a rat model of chronic sciatic nerve constriction injury (CCI)." | 3.72 | Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury. ( Bo-Hua, Z; He, L; Hong-Ju, Y; Jun-Wei, W; Nan, Z; Wei-Guo, S; Wei-Xiu, Y; Zhe-Hui, G; Zheng-Hua, G; Zhi-Pu, L; Zhong-Wei, J, 2004) |
| "To determine, using electrophysiological measures of visual system function, whether oral daily dosing of memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 3.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. ( Chun, T; Hare, WA; Lai, RK; Ruiz, G; Ton, H; Wheeler, L; WoldeMussie, E, 2004) |
| "To determine, using anatomic measurements, whether daily oral dosing with memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 3.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. ( Feldmann, B; Hare, WA; Ruiz, G; Ton, H; Weinreb, RN; Wheeler, L; Wijono, M; WoldeMussie, E; Zangwill, L, 2004) |
| "Microinjections of glutamic acid, serotonin, and sulpiride in the ventromedial hypothalamus reduced anxiety in an illuminated platform avoidance task in rats, while dopamine, apomorphine, picrotoxin, and memantine increased it." | 3.71 | The role of neurochemical mechanisms of ventromedial hypothalamus in various models of anxiety in rats. ( Gordienko, DV; Krivobok, GK; Pankrat'ev, DV; Talalaenko, AN; Zinkovich, II, 2001) |
| "Retinal ischemia increased vitreous concentrations of glutamate and glycine." | 3.70 | Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. ( Bach, M; Feuerstein, TJ; Knörle, R; Lagrèze, WA, 1998) |
| " The aim of the present study was to evaluate the effects of an uncompetitive NMDA receptor antagonist memantine, in animal models of alcoholism." | 3.70 | Ethanol-reinforced behaviour in the rat: effects of uncompetitive NMDA receptor antagonist, memantine. ( Bienkowski, P; Danysz, W; Dyr, W; Koros, E; Kostowski, W; Piasecki, J, 1998) |
| "To evaluate the neuroprotective effect of memantine and dizocilpine, which are noncompetitive open-channel blockers of the N-methyl-D-aspartate (NMDA) receptor, on glaucomatous optic neuropathy in an experimental glaucoma model in the rat." | 3.70 | [Neuroprotective effect of N-methyl-D-aspartate receptor antagonists in an experimental glaucoma model in the rat]. ( Gu, Z; Kawase, C; Kawase, K; Kitazawa, Y; Matsubara, M; Sawada, A; Yamamoto, T, 2000) |
| "The most prevalent of all dementias is Alzheimer's disease, a progressive neurodegenerative disease that presents with deficits in memory, cognition, motor skills, and a general decline in the quality of life." | 2.55 | Alzheimer's disease in the zebrafish: where can we take it? ( Caramillo, EM; Echevarria, DJ, 2017) |
| "Using Alzheimer's disease as an example, this review employs a networks-based method to assess repeatability of outcomes across species, by intervention and mechanism." | 2.52 | Improving the predictive value of interventional animal models data. ( Zeiss, CJ, 2015) |
| "Trisomy 21 was first described as a syndrome in the middle of the nineteenth century and associated to a chromosomic anomaly one hundred years later: the most salient feature of this syndrome is a mental retardation of variable intensity." | 2.46 | [New perspectives on molecular and genic therapies in Down syndrome]. ( Delabar, JM, 2010) |
| "Alzheimer's disease is the leading cause of dementia in the elderly, presenting itself clinically by progressive loss of memory and learning." | 2.43 | Altered synaptic function in Alzheimer's disease. ( Bell, KF; Claudio Cuello, A, 2006) |
| "Thymoquinone (TQ) has broad biological functions, including antiinflammatory, antioxidant, neuroprotective properties." | 1.91 | Effects of thymoquinone and memantine alone and in combination on memory and hippocampal morphology in rats with streptozotocin-induced Alzheimer's disease. ( Akçay, E; Çakir, Z; Gevrek, F; Özsoy, Ş, 2023) |
| "Treatment with memantine and vitamin D can protect cortical axons from exposure to amyloid-β and glutamate toxicity, suggesting this combination may mitigate altered gait in AD." | 1.72 | Effects of Memantine and High Dose Vitamin D on Gait in Male APP/PS1 Alzheimer's Disease Mice Following Vitamin D Deprivation. ( Annweiler, C; Bartha, R; Beauchet, O; Bellyou, M; Broberg, DN; Montero-Odasso, M; Wong, D, 2022) |
| "Memantine treatment did not affect compulsive checking nor frontostriatal structural and functional connectivity in the quinpirole-induced adolescent rat model." | 1.72 | Memantine treatment does not affect compulsive behavior or frontostriatal connectivity in an adolescent rat model for quinpirole-induced compulsive checking behavior. ( Blezer, ELA; Buitelaar, JK; Dijkhuizen, RM; Glennon, JC; Otte, WM; Smeele, CE; Straathof, M; van der Toorn, A; van Heijningen, C, 2022) |
| "A mouse model of Lafora disease (Epm2b-/-) was used to check the putative beneficial effect of different drugs aimed to ameliorate the alterations in glutamatergic transmission and/or neuroinflammation present in the model." | 1.72 | Pharmacological Modulation of Glutamatergic and Neuroinflammatory Pathways in a Lafora Disease Mouse Model. ( Campos, Á; Heredia, M; Mollá, B; Sanz, P, 2022) |
| "Current therapies in Alzheimer's disease (AD), including Memantine, have proven to be only symptomatic but not curative or disease modifying." | 1.62 | Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer's Disease. ( Bouchet, M; Couly, S; Denus, M; Maurice, T; Rubinstenn, G, 2021) |
| " T-006 improved cognitive ability after long-term administration in two AD mouse models and targeted mitochondrial-related protein alpha-F1-ATP synthase (ATP5A)." | 1.62 | The Tetramethylpyrazine Analogue T-006 Alleviates Cognitive Deficits by Inhibition of Tau Expression and Phosphorylation in Transgenic Mice Modeling Alzheimer's Disease. ( Chen, H; Cheng, J; Guo, B; Huang, C; Su, Z; Sun, Y; Wang, Y; Wu, J; Wu, L; Yang, X; Zhang, G; Zhang, Z; Zhu, Z, 2021) |
| "Seizures were evaluated by video-EEG during one hour and scored according to Racine scale." | 1.62 | Effect of Memantine on Pentylenetetrazol-induced Seizures and EEG Profile in Animal Model of Cortical Malformation. ( Cagliari Zenki, K; Calcagnotto, ME; Klippel Zanona, Q; Lazzarotto, G, 2021) |
| "Memantine has demonstrated beneficial effects on several types of brain insults via therapeutic mechanisms mainly related to its activity as a receptor antagonist of N-methyl-d-aspartate." | 1.62 | Memantine protects blood-brain barrier integrity and attenuates neurological deficits through inhibiting nitric oxide synthase ser1412 phosphorylation in intracerebral hemorrhage rats: involvement of peroxynitrite-related matrix metalloproteinase-9/NLRP3 ( Chen, M; Chen, X; Chen, Z; Gao, Z; Huang, H; Mou, Y; Song, M; Xiang, X; Xie, T; Xie, X, 2021) |
| " This was not observed when memantine treatment was combined with vitamin D enrichment." | 1.62 | Effect of Memantine Treatment and Combination with Vitamin D Supplementation on Body Composition in the APP/PS1 Mouse Model of Alzheimer's Disease Following Chronic Vitamin D Deficiency. ( Annweiler, C; Bartha, R; Beauchet, O; Bellyou, M; Broberg, DN; Doad, J; Holdsworth, DW; Montero-Odasso, M; Norley, CJD; Umoh, JU; Wong, D, 2021) |
| "Memantine (Mem) is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist used in the treatment of Alzheimer's disease." | 1.62 | [Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment]. ( Aoki, Y; Han, LK; Kaneda, M; Michihara, S; Shimoyama, T; Takahashi, R, 2021) |
| "Memantine treatment was able both to reverse the memory deficits and to reduce the excessive intake of palatable diet and the withdrawal-induced hypophagia in food cycling rats." | 1.56 | Withdrawal from Extended, Intermittent Access to A Highly Palatable Diet Impairs Hippocampal Memory Function and Neurogenesis: Effects of Memantine. ( Abdullatif, AA; Cottone, P; Ferragud, A; Sabino, V; Velázquez-Sánchez, C, 2020) |
| "Memantine was administered by oral gavage." | 1.56 | Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders. ( Chan, KH; Kwan, JS; Ma, OK; Tang, CH; Yick, LW, 2020) |
| "Memantine was administered in daily intraperitoneal injections for 13 days, on alternate days, either 1-h before-"before testing" sessions-or immediately after a 30-min session-"after testing" sessions." | 1.56 | Memantine effects on ingestion microstructure and the effect of administration time: A within-subject study. ( D'Aquila, PS; Galistu, A, 2020) |
| " One of the major adverse effects of cisplatin is its neurotoxicity." | 1.56 | Effect of memantine hydrochloride on cisplatin-induced neurobehavioral toxicity in mice. ( Al-Baggou, BK; Salih, NA, 2020) |
| "Background Tauopathies, including Alzheimer's disease (AD), are multifactorial diseases with strong phenotypic and genetic heterogeneity." | 1.51 | Pore-former enabled seeding of tau in rats: Alleviation by memantine and lithium chloride. ( Gasiorowska, A; Koss, DJ; Mietelska-Porowska, A; Niewiadomska, G; Palasz, E; Riedel, G, 2019) |
| "Memantine pretreatment (18 mg/kg sc) produced in rats poisoned with soman significantly better protective ratios (PRs) than the two carbamates - 1." | 1.51 | Prophylactic potential of memantine against soman poisoning in rats. ( Bokonjić, D; Jokanović, M; Kilibarda, V; Škrbić, R; Stojiljković, MP; Vulović, M, 2019) |
| "Moreover, MN-08 also alleviated cerebral vasospasm in a cisterna magna single-injection model in rabbits." | 1.51 | The dual-functional memantine nitrate MN-08 alleviates cerebral vasospasm and brain injury in experimental subarachnoid haemorrhage models. ( Guo, B; Han, Y; Ju, J; Li, N; Li, S; Liu, Z; Luo, F; Mak, S; Sun, Y; Wang, Y; Wu, L; Yang, X; Zhang, G; Zhang, Z; Zhou, Q; Zhu, Z, 2019) |
| "Treatment with memantine also corresponded to normal NMDAR expression after rmTBI." | 1.48 | Memantine improves outcomes after repetitive traumatic brain injury. ( Alcon, S; Hashim, J; Mannix, R; Meehan, WP; Mei, Z; Qiu, J; Rotenberg, A; Sun, Y, 2018) |
| " Since neuronal death following HIE occurs by a cascade of events triggered by activation of glutamate receptors, we used in vitro and in vivo models of HIE to examine whether the AMPA/kainate receptor antagonist topiramate and the NMDA receptor antagonist memantine could exert neuroprotective effects, alone or in combination with hypothermia." | 1.48 | Neuroprotective effects of topiramate and memantine in combination with hypothermia in hypoxic-ischemic brain injury in vitro and in vivo. ( Catarzi, S; Filippi, L; Gerace, E; Guerrini, R; Landucci, E; Pellegrini-Giampietro, DE, 2018) |
| "Memantine followed a slower release profile from the NPs against the free drug solution, allowing to reduce drug administration frequency in vivo." | 1.48 | Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization. ( Calpena, AC; Camins, A; Cano, A; Carmona, N; Egea, MA; Espina, M; Ettcheto, M; García, ML; Sánchez-López, E; Silva, AM; Souto, EB, 2018) |
| "Memantine treatment stabilized ventricular enlargement in both low and high dose groups." | 1.48 | Memantine treatment of juvenile rats with kaolin-induced hydrocephalus. ( Del Bigio, MR; Di Curzio, DL; Mao, X; Nagra, G, 2018) |
| " These changes (except for those in NE and Bax) were reversed with chronic administration of MEM." | 1.48 | Memantine ameliorates depressive-like behaviors by regulating hippocampal cell proliferation and neuroprotection in olfactory bulbectomized mice. ( Arai, Y; Isono, J; Kadota, S; Nakagawasai, O; Nemoto, W; Odaira, T; Sakuma, W; Tadano, T; Takahashi, K; Tan-No, K, 2018) |
| "Memantine is a drug approved for the treatment of moderate-to-severe Alzheimer's disease (AD), and there is ongoing research on the potential expansion of its clinical applicability." | 1.46 | Pharmacokinetic Properties of Memantine after a Single Intraperitoneal Administration and Multiple Oral Doses in Euploid Mice and in the Ts65Dn Mouse Model of Down's Syndrome. ( Bederman, IR; Costa, ACS; Victorino, DB, 2017) |
| "Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist used to treat Alzheimer's disease." | 1.43 | Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats. ( Bae, CS; Cho, IH; Choi, BM; Kim, EJ; Kim, SH; Lee, SH; Noh, GJ; Noh, YH; Park, WD, 2016) |
| "Metabolic syndrome (MetS) and Type 2 diabetes mellitus (T2DM) increase risk for Alzheimer's disease (AD)." | 1.43 | Elevated glucose and oligomeric β-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation. ( Akhtar, MW; Ambasudhan, R; Chon, K; Dolatabadi, N; Lee, MS; Lipton, SA; McKercher, SR; Nakamura, T; Parker, J; Sanz-Blasco, S; Soussou, W, 2016) |
| "Gentamicin was injected into the left cochleae of guinea pigs to induce apoptosis of SGCs; the contralateral cochleae served as controls." | 1.43 | Effects of Memantine on Aminoglycoside-Induced Apoptosis of Spiral Ganglion Cells in Guinea Pigs. ( Bae, WY; Hur, DY; Kim, BY; Kim, JR; Koh, TK; Lee, TH; Park, GB, 2016) |
| "Treatment with memantine has significantly attenuated prenatal valproic acid-induced reduction in social interaction, spontaneous alteration, exploratory activity intestinal motility, serotonin levels and prefrontal cortex mitochondrial complex activity." | 1.43 | Memantine ameliorates autistic behavior, biochemistry & blood brain barrier impairments in rats. ( Kumar, H; Sharma, B, 2016) |
| " Although these compounds are extremely toxic agents, the search for novel antidotes remains extremely limited." | 1.43 | Modeling and simulation of organophosphate-induced neurotoxicity: Prediction and validation by experimental studies. ( Ambert, N; Barbier, L; Baudry, M; Bischoff, S; Bouteiller, JM; Dadak, S; Dorandeu, F; Fagni, L; Greget, R; Lauga, F; Legendre, A; Linossier-Pierre, S; Moussaoui, S; Pernot, F, 2016) |
| "Memantine has been approved for moderate to severe AD, but evidence indicates that it does not modify disease progression." | 1.43 | Insulin potentiates the therapeutic effect of memantine against central STZ-induced spatial learning and memory deficit. ( Bahramian, A; Moosavi, M; Namavar, MR; Rastegar, K, 2016) |
| "Memantine was used as a positive control." | 1.43 | Low dose of L-glutamic acid attenuated the neurological dysfunctions and excitotoxicity in bilateral common carotid artery occluded mice. ( Abdul, KK; Justin, A; Ramanathan, M, 2016) |
| "Alcoholism is a chronic relapsing disorder with consequences on health and that requires more effective treatments." | 1.42 | Memantine reduces alcohol drinking but not relapse in alcohol-dependent rats. ( Alaux-Cantin, S; Buttolo, R; Houchi, H; Jeanblanc, J; Naassila, M, 2015) |
| "Pretreatment of memantine hydrochloride (10-30 mg/kg." | 1.42 | Memantine delayed N-methyl-D-aspartate -induced convulsions in neonatal rats. ( Chopra, K; Dhir, A, 2015) |
| "Delayed cerebral vasospasm is an important pathological feature of subarachnoid hemorrhage (SAH)." | 1.42 | Memantine Attenuates Delayed Vasospasm after Experimental Subarachnoid Hemorrhage via Modulating Endothelial Nitric Oxide Synthase. ( Huang, CY; Pan, CH; Shan, YS; Tsai, KJ; Wang, LC, 2015) |
| "Memantine is a low-affinity voltage-dependent noncompetitive antagonist at glutamatergic NMDA receptors." | 1.42 | Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil. ( Akishita, M; Ogawa, S; Ota, H; Ouchi, Y, 2015) |
| "Treatment with memantine, a noncompetitive NMDA receptor antagonist which is an approved drug for treatment of Alzheimer's disease, rescued protein phosphatase-2A activity by decreasing its demethylation at Leu309 selectively and attenuated Alzheimer's disease-like pathology and cognitive impairment in adeno-associated virus vector-1-I1PP2A rats." | 1.42 | Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment. ( Blanchard, J; Grundke-Iqbal, I; Iqbal, K; Wang, X, 2015) |
| " It is concluded that co-administration of Vit B12 and morphine could reduce tolerance to analgesic effect of morphine chronic administration and also reduce its withdrawal symptoms." | 1.40 | Effect of cyanocobalamin (vitamin B12) in the induction and expression of morphine tolerance and dependence in mice. ( Etemad, L; Ghazanfari, S; Hosseinzadeh, H; Imenshahidi, M; Moshiri, M, 2014) |
| "Dextromethorphan and memantine have been administered to animals after spinal nerve ligation (SNL) to evaluate their antinociceptive/cognitive effects and associated molecular events, including the phosphorylation of several tyrosine (pTyr(1336), pTyr(1472)) residues in the NR2B NMDAR subunit." | 1.40 | Low doses of dextromethorphan have a beneficial effect in the treatment of neuropathic pain. ( Chalus, M; Daulhac, L; Dupuis, A; Eschalier, A; Etienne, M; Morel, V; Pickering, G; Privat, AM, 2014) |
| "As dementia and depression are co-morbid, we evaluated if this combination would have an effect on cognition." | 1.40 | Role of glutamate and advantages of combining memantine with a 5HT6 ligand in a model of depression. ( Abraham, R; Nirogi, R; Shinde, A, 2014) |
| "Treatment with memantine or E2 significantly reduced infarct volume by >40% and significantly improved neurological function while treatment with TMP had no effect." | 1.40 | The neuroprotective effect of 17β-estradiol is independent of its antioxidative properties. ( Gröger, M; Plesnila, N, 2014) |
| " In concert with other studies showing the anti-inflammatory and protective effect of FTY720 in some neurodegenerative disorders like ischemia, we have recently shown that FTY720 chronic administration prevents from impairment of spatial learning and memory in AD rats." | 1.39 | Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: comparison with memantine. ( Ahmadiani, A; Chik, Z; Dargahi, L; Hemmati, F; Mohamed, Z; Naidu, M; Nasoohi, S; Omidbakhsh, R, 2013) |
| "Memantine is a N-methyl-D-aspartic acid receptor (NMDAR) channel blocker that binds to dizocilpine sites and appears well tolerated during chronic use." | 1.39 | Memantine and dizocilpine interactions with antinociceptive or discriminative stimulus effects of morphine in rats after acute or chronic treatment with morphine. ( Chen, Y; Evola, M; Young, AM, 2013) |
| "Alzheimer's disease is characterized by a progressive decline in cognitive function and involves β-amyloid (Aβ) in its pathogenesis." | 1.39 | Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine. ( Matsuoka, N; Nagakura, A; Shitaka, Y; Yarimizu, J, 2013) |
| "Current treatment of Alzheimer's disease rests on cholinergic and anti-glutamatergic substances." | 1.38 | Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of Alzheimer's disease. ( Neumeister, KL; Riepe, MW, 2012) |
| "However, patients with Alzheimer's disease seem not only to forget events but also to express false confidence in remembering events that have never happened." | 1.38 | False recognition in a mouse model of Alzheimer's disease: rescue with sensory restriction and memantine. ( Bussey, TJ; Cho, K; Heath, CJ; McTighe, SM; Romberg, C; Saksida, LM; Whitcomb, DJ, 2012) |
| "Memantine treatment of Fmr1-KO CGCs promoted cell adhesion properties." | 1.38 | The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. ( Brown, WT; Dobkin, C; Li, X; Malik, M; Sheikh, AM; Wei, H, 2012) |
| "Currently there is no treatment for juvenile Batten disease, a fatal childhood neurodegenerative disorder caused by mutations in the CLN3 gene." | 1.38 | Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease. ( Cooper, JD; Kovács, AD; Pearce, DA; Ramji, S; Saje, A; Wong, A, 2012) |
| "Memantine treatment improved spatial and recognition memory performance in the Ts65Dn mice, though not to the level of normosomic littermate controls." | 1.37 | Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. ( Bimonte-Nelson, H; Boger, H; Granholm, AC; Lockrow, J, 2011) |
| "Schizophrenia is a severe, disabling chronic disorder affecting approximately 1% of the population." | 1.37 | Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist. ( Dedeurwaerdere, S; Langlois, X; Pemberton, D; Straetemans, R; Wintmolders, C, 2011) |
| " Ouabain-induced hyperlocomotion was normalized with acute and chronic lithium and chronic use of memantine." | 1.37 | Memantine reduces mania-like symptoms in animal models. ( Banerjee, P; El-Mallakh, RS; Gao, Y; Herman, L; Hougland, T; Lei, Z; Lord, J; Payne, RS; Schurr, A, 2011) |
| "Memantine (20 mg/kg) was administrated i." | 1.37 | Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model. ( Quan, MN; Wang, YY; Yang, Z; Zhang, N; Zhang, T, 2011) |
| "Methadone only treated rats had a mean paw withdrawal latency significantly lower than the corresponding values for saline on days 8, 9, 10, 11, 12, 14, and 17 (P<0." | 1.36 | Model of methadone-induced hyperalgesia in rats and effect of memantine. ( Hay, JL; Irvine, R; Kaboutari, J; Salem, A; White, JM, 2010) |
| "Memantine treatment also was associated with a decline in the levels of total tau and hyperphosphorylated tau." | 1.36 | Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. ( Albrecht, M; Banerjee, P; Billings, LM; Green, KN; Gupta, S; Kitazawa, M; LaFerla, FM; Martinez-Coria, H; Parsons, CG; Rammes, G, 2010) |
| "The mechanism of cerebral hypoxia-induced myoclonic jerks is not known." | 1.36 | Memantine exacerbates myoclonic jerks in a rat model of posthypoxic myoclonus. ( Tai, KK; Truong, DD, 2010) |
| "Memantine (16 mg/kg) was injected intraperitoneally into rats with SCI and OAD." | 1.36 | Effect of memantine on overactive detrusor in rats with spinal cord injury. ( Kömür, O; Ozkan, L; Ozkürkçügil, C, 2010) |
| "Hyperammonemia is a main contributor to brain herniation and mortality in acute liver failure (ALF)." | 1.35 | Acute liver failure-induced death of rats is delayed or prevented by blocking NMDA receptors in brain. ( Agusti, A; Boix, J; Cauli, O; Felipo, V; Piedrafita, B; Rodrigo, R, 2008) |
| "Memantine has also been shown to reduce the levels of amyloid beta (A beta) peptides in human neuroblastoma cells as well as to inhibit A beta oligomer-induced synaptic loss." | 1.35 | Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. ( Banerjee, P; Douadi, M; Li, YS; Quartermain, D; Scholtzova, H; Sigurdsson, EM; Wadghiri, YZ; Wisniewski, T, 2008) |
| "The rest of the rats with hydrocephalus received serum physiologic (hydrocephalus group, HG)." | 1.35 | The effect of N-methyl-D-aspartate receptor antagonist (memantine) on esophageal and gastric smooth muscle: functional investigation in a rat hydrocephalus model. ( Bektaş, AO; Etus, V; Göçmez, SS; Tugay, M; Tugay, S; Utkan, T, 2008) |
| " Here we determined the antinociceptive effect of chronic administration of neramexane and compared its effect with that of memantine and gabapentin in a rat model of diabetic neuropathic pain." | 1.35 | Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain. ( Chen, SR; Pan, HL; Samoriski, G, 2009) |
| "Memantine is a safe non-competitive NMDA receptor blocker characterized by its low affinity and fast unblocking kinetics." | 1.35 | Neuroprotective effect of memantine combined with topiramate in hypoxic-ischemic brain injury. ( Lin, N; Liu, C; Qiu, Y; Wu, B, 2009) |
| "Co-treatment with memantine reversed the activation of the astrocytes and microglia, thus attenuating the PAD2 increment." | 1.35 | Increased expression of PAD2 after repeated intracerebroventricular infusions of soluble Abeta(25-35) in the Alzheimer's disease model rat brain: effect of memantine. ( Arif, M; Kato, T, 2009) |
| "It is still unknown whether neuropathic pain could relate to behavioral and neurochemical alterations in the central nervous system." | 1.35 | Effect of memantine on the levels of neuropeptides and microglial cells in the brain regions of rats with neuropathic pain. ( Chikuma, T; Kato, T; Muramatsu, M; Takeda, K, 2009) |
| "Treatment with memantine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist significantly attenuated Abeta(25-35)-induced changes of neuropeptides, their metabolizing enzymes, glial marker proteins, and activation of iNOS." | 1.35 | Effects of memantine on soluble Alphabeta(25-35)-induced changes in peptidergic and glial cells in Alzheimer's disease model rat brain regions. ( Ahmed, MM; Arif, M; Chikuma, T; Kato, T; Nakazato, M; Smith, MA, 2009) |
| "Memantine was administered two weeks post infection, at peak viremia, in order to prevent early NMDA receptor activation due to immune mediators." | 1.35 | Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. ( Kneitz, S; Koutsilieri, E; Meisner, F; Neuen-Jacob, E; Riederer, P; Scheller, C; Sopper, S; ter Meulen, V, 2008) |
| "Treatment of cerebral edema could not be investigated because formation of cerebral edema could not be proven statistically." | 1.35 | Effects of memantine and MK-801 on ischemia in an experimental model of acute subdural hematoma. ( Aktan, D; Arica, O; Görgülü, A; Kirin, T; Sencer, A, 2008) |
| "Treatment with memantine resulted in a significant reduction in RGC loss and NR1 expression in the eyes of rats COHT." | 1.34 | Expression of N-methyl-d-aspartate receptor 1 in rats with chronic ocular hypertension. ( Jung, SW; Kim, JH; Lee, NY; Park, CK, 2007) |
| " Higher dosages often did not exert beneficial effects in accordance with inverted U-shaped dose-response curves described for cholinomimetics." | 1.33 | Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. ( Abramowski, D; De Deyn, PP; Staufenbiel, M; Van Dam, D, 2005) |
| "Formation of senile plaques composed of amyloid beta peptide, a pathological hallmark of Alzheimer disease, in human brains precedes disease onset by many years." | 1.33 | 19F and 1H MRI detection of amyloid beta plaques in vivo. ( Higuchi, M; Iwata, N; Matsuba, Y; Saido, TC; Sasamoto, K; Sato, K, 2005) |
| "Memantine treatment significantly reduced lipid peroxidation levels in the treatment group compared with other groups (P<0." | 1.33 | The effects of memantine on lipid peroxidation following closed-head trauma in rats. ( Cobanoğlu, S; Görgülü, A; Kiriş, T; Ozsüer, H, 2005) |
| "Intracerebral hemorrhage was induced via the infusion of collagenase into the left basal ganglia of adult rats." | 1.33 | Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement. ( Chu, K; Jung, KH; Kim, EH; Kim, J; Kim, M; Kim, SJ; Ko, SY; Lee, ST; Roh, JK; Sinn, DI, 2006) |
| "Memantine treatment significantly delayed the disease progression and increased the life span of SOD1(G93A) mice, from 121." | 1.33 | Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. ( Wang, R; Zhang, D, 2005) |
| "Huntington's disease has an increase in the activated calpain, which is enhanced by the NMDA receptor activation." | 1.33 | Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. ( Chu, K; Jung, KH; Kang, L; Kim, M; Ko, SY; Lee, ST; Park, JE, 2006) |
| "NMDA-induced convulsions were effectively prevented by both mono- and dications, while only dications were effective against kainate convulsions." | 1.32 | The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals. ( Gmiro, VE; Gorbunova, LV; Lukomskaya, NY; Rukoyatkina, NI, 2003) |
| "Pretreatment with risperidone (0." | 1.32 | Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2004) |
| "Memantine has been used clinically in the treatment of Parkinson's disease and spasticity for a number of years." | 1.30 | Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. ( Le, DA; Lipton, SA; Sathi, S; Stieg, PE; Warach, S, 1999) |
| "Persistent hyperalgesia induced by chronic constrictive injury (CCI) to the sciatic nerve was significantly reduced for up to 14 days by prophylactic administration of memantine (3." | 1.29 | The clinically tested N-methyl-D-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy. ( Eisenberg, E; LaCross, S; Strassman, AM, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (4.15) | 18.2507 |
| 2000's | 59 (24.48) | 29.6817 |
| 2010's | 132 (54.77) | 24.3611 |
| 2020's | 40 (16.60) | 2.80 |
| Authors | Studies |
|---|---|
| Saiki, R | 1 |
| Yoshizawa, Y | 1 |
| Minarini, A | 2 |
| Milelli, A | 1 |
| Marchetti, C | 1 |
| Tumiatti, V | 1 |
| Toida, T | 1 |
| Kashiwagi, K | 1 |
| Igarashi, K | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Jiang, X | 3 |
| Guo, J | 1 |
| Lv, Y | 2 |
| Yao, C | 2 |
| Zhang, C | 4 |
| Mi, Z | 1 |
| Shi, Y | 1 |
| Gu, J | 1 |
| Zhou, T | 1 |
| Bai, R | 1 |
| Xie, Y | 3 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 4 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Turcu, AL | 2 |
| Companys-Alemany, J | 2 |
| Phillips, MB | 1 |
| Patel, DS | 1 |
| Griñán-Ferré, C | 2 |
| Loza, MI | 1 |
| Brea, JM | 1 |
| Pérez, B | 1 |
| Soto, D | 1 |
| Sureda, FX | 1 |
| Kurnikova, MG | 1 |
| Johnson, JW | 1 |
| Pallàs, M | 2 |
| Vázquez, S | 2 |
| Song, Z | 1 |
| Bian, Z | 1 |
| Zhang, Z | 7 |
| Wang, X | 8 |
| Zhu, A | 1 |
| Zhu, G | 2 |
| Fan, W | 1 |
| Liu, Z | 6 |
| Chen, J | 3 |
| Liu, S | 2 |
| Chen, T | 1 |
| Li, Z | 3 |
| Lin, D | 1 |
| Broberg, DN | 2 |
| Wong, D | 2 |
| Bellyou, M | 2 |
| Montero-Odasso, M | 2 |
| Beauchet, O | 2 |
| Annweiler, C | 2 |
| Bartha, R | 2 |
| Straathof, M | 1 |
| Blezer, ELA | 1 |
| Smeele, CE | 1 |
| van Heijningen, C | 1 |
| van der Toorn, A | 1 |
| Buitelaar, JK | 1 |
| Glennon, JC | 1 |
| Otte, WM | 1 |
| Dijkhuizen, RM | 1 |
| Moriguchi, S | 2 |
| Inagaki, R | 1 |
| Saito, T | 2 |
| Saido, TC | 3 |
| Fukunaga, K | 2 |
| Andrzejewski, K | 1 |
| Jampolska, M | 1 |
| Mojzych, I | 1 |
| Conde, SV | 1 |
| Kaczyńska, K | 1 |
| Mollá, B | 1 |
| Heredia, M | 1 |
| Campos, Á | 1 |
| Sanz, P | 1 |
| Albayrak, G | 2 |
| Bali, EB | 2 |
| Korkmaz, FD | 2 |
| Bağrıaçık, EÜ | 2 |
| Zohny, SM | 1 |
| Habib, MZ | 1 |
| Mohamad, MI | 1 |
| Elayat, WM | 1 |
| Elhossiny, RM | 1 |
| El-Salam, MFA | 1 |
| Hassan, GAM | 1 |
| Aboul-Fotouh, S | 1 |
| Anoush, M | 1 |
| Bijani, S | 1 |
| Moslemifar, F | 1 |
| Jahanpour, F | 1 |
| Kalantari-Hesari, A | 1 |
| Hosseini, MJ | 1 |
| Özsoy, Ş | 1 |
| Çakir, Z | 1 |
| Akçay, E | 1 |
| Gevrek, F | 1 |
| Jürgenson, M | 1 |
| Zharkovskaja, T | 1 |
| Noortoots, A | 1 |
| Morozova, M | 1 |
| Beniashvili, A | 1 |
| Zapolski, M | 1 |
| Zharkovsky, A | 1 |
| Gothwal, A | 1 |
| Kumar, H | 2 |
| Nakhate, KT | 1 |
| Dutta, A | 1 |
| Borah, A | 1 |
| Gupta, U | 1 |
| Radwan, RR | 1 |
| Abdel Ghaffar, AM | 1 |
| Ali, HE | 1 |
| Wang, QJ | 1 |
| Shen, YE | 1 |
| Fu, S | 2 |
| Zhang, X | 8 |
| Zhang, YN | 1 |
| Wang, RT | 1 |
| Bures, J | 1 |
| Kvetina, J | 1 |
| Radochova, V | 1 |
| Tacheci, I | 1 |
| Peterova, E | 1 |
| Herman, D | 1 |
| Dolezal, R | 1 |
| Kopacova, M | 1 |
| Rejchrt, S | 1 |
| Douda, T | 1 |
| Sestak, V | 1 |
| Douda, L | 1 |
| Karasova, JZ | 1 |
| Potasiewicz, A | 2 |
| Krawczyk, M | 1 |
| Gzielo, K | 1 |
| Popik, P | 3 |
| Nikiforuk, A | 2 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 1 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Jiménez, A | 1 |
| Yan, Z | 1 |
| Zhou, L | 1 |
| Zhao, Y | 3 |
| Wang, J | 7 |
| Huang, L | 2 |
| Hu, K | 1 |
| Liu, H | 4 |
| Wang, H | 4 |
| Guo, Z | 1 |
| Song, Y | 1 |
| Huang, H | 5 |
| Yang, R | 1 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 2 |
| Wu, S | 1 |
| Cheng, T | 1 |
| Zhou, X | 2 |
| Wang, B | 4 |
| Zhang, Q | 5 |
| Wu, X | 2 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Hashimoto, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Jiao, J | 3 |
| Gai, QY | 3 |
| Wang, W | 2 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Yao, LP | 1 |
| Qin, QP | 1 |
| Wang, ZY | 1 |
| Liu, J | 5 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 1 |
| Zhu, J | 2 |
| Jiang, H | 1 |
| He, C | 2 |
| Xiao, Z | 1 |
| Xu, J | 2 |
| Sun, Q | 1 |
| Han, D | 1 |
| Lei, H | 1 |
| Zhao, K | 2 |
| Zhu, L | 1 |
| Li, X | 5 |
| Fu, H | 2 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Sun, Y | 8 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Lin, L | 3 |
| Shao, J | 1 |
| Sun, M | 1 |
| Xu, G | 1 |
| Xu, N | 1 |
| Wang, R | 2 |
| He, H | 1 |
| Dong, X | 2 |
| Yang, M | 3 |
| Yang, Q | 1 |
| Duan, S | 1 |
| Yu, Y | 2 |
| Han, J | 3 |
| Chen, L | 2 |
| Yang, X | 4 |
| Wang, T | 2 |
| Campbell, DA | 1 |
| Gao, K | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 1 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 4 |
| Yao, L | 2 |
| Sun, L | 3 |
| Zhu, Z | 3 |
| Naren, N | 1 |
| Zhang, XX | 2 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Lee, JH | 2 |
| Yoo, JS | 1 |
| Kim, Y | 1 |
| Kim, JS | 2 |
| Lee, EJ | 1 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simon, M | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 1 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 1 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Yang, S | 1 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 1 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Xu, W | 2 |
| Gao, S | 1 |
| Zhai, X | 1 |
| Wang, C | 3 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Lu, Y | 1 |
| Yan, R | 1 |
| Zhang, Y | 8 |
| Hu, Z | 1 |
| You, Q | 1 |
| Cai, Q | 1 |
| Yang, D | 1 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 1 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 1 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Park, JI | 1 |
| Wang, Y | 11 |
| Zhao, R | 1 |
| Gu, Z | 2 |
| Dong, C | 2 |
| Guo, G | 1 |
| Li, L | 6 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Zhu, X | 2 |
| Huang, X | 4 |
| Xu, H | 4 |
| Yang, G | 2 |
| Lin, Z | 1 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 2 |
| An, Z | 1 |
| Jiang, J | 2 |
| Li, J | 8 |
| Du, S | 1 |
| Zhou, H | 1 |
| Cui, J | 1 |
| Wu, W | 1 |
| Liu, Y | 8 |
| Song, J | 1 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 1 |
| Choi, GH | 1 |
| Choi, J | 1 |
| Lim, YS | 1 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Zhao, L | 1 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 1 |
| Yang, P | 1 |
| Yu, X | 2 |
| Wu, Y | 2 |
| Zhang, H | 1 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Wu, G | 2 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 2 |
| Carreno, J | 1 |
| Kloner, RA | 1 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 2 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 1 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 2 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 1 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Sun, J | 2 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 2 |
| Zheng, S | 2 |
| Ma, L | 1 |
| Wang, L | 4 |
| Hu, T | 1 |
| Wang, F | 1 |
| Han, Z | 1 |
| Yin, Z | 1 |
| Ge, X | 1 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 1 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Yang, Y | 3 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 1 |
| Li, Y | 5 |
| Du, Q | 1 |
| Hao, P | 1 |
| Cao, X | 1 |
| Li, CX | 1 |
| Zhao, S | 1 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Guo, L | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 1 |
| Tang, J | 3 |
| Chen, Z | 3 |
| Luo, W | 1 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 1 |
| Zhou, Z | 2 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 1 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Zhang, J | 3 |
| Guo, W | 1 |
| Liu, M | 2 |
| Liu, T | 2 |
| Chen, D | 5 |
| Luo, K | 1 |
| He, Z | 2 |
| Zheng, G | 1 |
| Xu, F | 1 |
| Sun, W | 2 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Shi, X | 1 |
| Kang, S | 1 |
| Duan, W | 1 |
| Zhang, S | 2 |
| Feng, J | 2 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 1 |
| Shang, Q | 1 |
| Zhao, W | 2 |
| Yang, Z | 3 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 1 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 1 |
| Quan, M | 1 |
| Dong, J | 1 |
| Bai, J | 1 |
| Han, R | 1 |
| Cai, Y | 1 |
| Lv, YQ | 1 |
| Chen, Q | 1 |
| Lyu, HD | 1 |
| Deng, L | 1 |
| Zhou, D | 1 |
| Xiao, X | 1 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Gao, F | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 1 |
| Otano, I | 1 |
| Alvarez, M | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 2 |
| Yu, Q | 1 |
| Zhou, C | 2 |
| Liu, C | 3 |
| Liu, W | 2 |
| Chen, W | 2 |
| Yin, Y | 1 |
| Li, CW | 1 |
| Hsu, JL | 1 |
| Zhou, Q | 2 |
| Hu, B | 1 |
| Fu, P | 1 |
| Atyah, M | 1 |
| Ma, Q | 2 |
| Xu, Y | 1 |
| Dong, Q | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Chen, X | 5 |
| Cao, Q | 1 |
| Yuan, X | 1 |
| Nie, W | 1 |
| Yang, J | 2 |
| Shao, B | 1 |
| Ma, X | 1 |
| Bi, Z | 1 |
| Liang, X | 1 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 1 |
| Wei, Y | 1 |
| Wei, X | 2 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 1 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 1 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 1 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 1 |
| Bi, W | 1 |
| Tang, H | 1 |
| Cui, Y | 2 |
| Zhang, L | 4 |
| Fan, H | 1 |
| Yu, H | 1 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 2 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Lee, C | 1 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 3 |
| Li, C | 2 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Jin, X | 1 |
| Pang, B | 1 |
| Liu, Q | 3 |
| Liu, X | 4 |
| Huang, Y | 3 |
| Josephine Fauci, A | 1 |
| Ma, Y | 1 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 2 |
| Chua, H | 1 |
| Wang, K | 1 |
| Ou, Y | 1 |
| Huang, M | 1 |
| Zhu, Y | 1 |
| Yu, J | 1 |
| Tian, J | 1 |
| Zhao, M | 1 |
| Hu, J | 1 |
| Zhang, B | 1 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 2 |
| Chi, T | 2 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 1 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Han, G | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Park, JH | 1 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 1 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 1 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 1 |
| Rimoldi, S | 1 |
| Noll, G | 1 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 1 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 1 |
| Kang, J | 1 |
| Park, S | 1 |
| Cho, JH | 1 |
| Oh, S | 1 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 1 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 2 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 2 |
| Levinger, I | 1 |
| Vogrin, S | 1 |
| Neil, CJ | 1 |
| Allen, JD | 1 |
| Yuan, R | 1 |
| Cai, B | 1 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Yang, C | 2 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 1 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 1 |
| Kim, MJ | 1 |
| Baek, SH | 1 |
| Choi, M | 1 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 2 |
| Lee, JO | 1 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 3 |
| Fang, Z | 1 |
| Wei, F | 1 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Guo, Y | 1 |
| Shen, Y | 1 |
| Wang, Q | 2 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 1 |
| Liang, H | 1 |
| Xu, X | 1 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 1 |
| Wang, P | 1 |
| Mi, K | 1 |
| Cheng, J | 2 |
| Gu, C | 1 |
| Huang, J | 2 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Zheng, Y | 2 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Zhou, Y | 3 |
| Xue, H | 1 |
| Zhang, W | 1 |
| Ruan, Z | 1 |
| Li, S | 3 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 1 |
| Kong, F | 1 |
| Lin, S | 1 |
| Wang, Z | 2 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Yan, X | 1 |
| Ma, C | 1 |
| Tang, Y | 2 |
| Kong, X | 1 |
| Lu, J | 1 |
| Zhang, M | 1 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 1 |
| Le Foll, B | 1 |
| Xia, Y | 1 |
| Chen, S | 1 |
| Luo, M | 1 |
| Wu, J | 2 |
| Cai, S | 1 |
| He, Y | 2 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Yuan, Q | 1 |
| Sherrell, PC | 1 |
| Bi, X | 1 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Xue, J | 1 |
| Wu, P | 1 |
| Xu, L | 1 |
| Yuan, Y | 1 |
| Luo, J | 2 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Hu, Y | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Srivastava, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, JS | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 1 |
| Zhang, G | 5 |
| Jiang, F | 1 |
| Meng, X | 1 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 1 |
| Tan, SJ | 1 |
| Xin, S | 1 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 1 |
| Yan, W | 1 |
| Luo, L | 1 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 2 |
| Hassan, HM | 1 |
| Jiang, Z | 1 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 1 |
| Bentley, RF | 1 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 1 |
| Liang, J | 1 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 1 |
| Chu, Q | 1 |
| Wu, MC | 1 |
| Lu, X | 1 |
| Wang, D | 1 |
| Hu, M | 1 |
| Shen, H | 1 |
| Yao, M | 1 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 1 |
| Xiong, X | 1 |
| Peng, X | 2 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 2 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Wang, HY | 1 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 1 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 1 |
| Sun, X | 1 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 3 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Gao, Y | 2 |
| Cao, WH | 1 |
| Lyu, J | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Dong, Z | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 1 |
| Li, LM | 1 |
| Pan, L | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 1 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 1 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 1 |
| Sun, YH | 1 |
| Zhang, HB | 1 |
| Ferragud, A | 1 |
| Velázquez-Sánchez, C | 2 |
| Abdullatif, AA | 1 |
| Sabino, V | 2 |
| Cottone, P | 2 |
| Amador, A | 1 |
| Bostick, CD | 1 |
| Olson, H | 1 |
| Peters, J | 1 |
| Camp, CR | 1 |
| Krizay, D | 1 |
| Han, W | 1 |
| Tang, W | 1 |
| Kanber, A | 1 |
| Kim, S | 1 |
| Teoh, J | 1 |
| Sah, M | 1 |
| Petri, S | 1 |
| Paek, H | 1 |
| Kim, A | 1 |
| Lutz, CM | 1 |
| Myers, SJ | 1 |
| Bhattacharya, S | 1 |
| Yuan, H | 1 |
| Goldstein, DB | 1 |
| Poduri, A | 1 |
| Boland, MJ | 1 |
| Traynelis, SF | 1 |
| Frankel, WN | 1 |
| Azadfar, P | 1 |
| Noormohammadi, Z | 1 |
| Noroozian, M | 1 |
| Eidi, A | 1 |
| Mortazavi, P | 1 |
| Yick, LW | 1 |
| Tang, CH | 1 |
| Ma, OK | 1 |
| Kwan, JS | 1 |
| Chan, KH | 1 |
| Spampanato, J | 1 |
| Bealer, SL | 1 |
| Smolik, M | 1 |
| Dudek, FE | 1 |
| Stazi, M | 1 |
| Wirths, O | 1 |
| Galistu, A | 1 |
| D'Aquila, PS | 1 |
| Couly, S | 1 |
| Denus, M | 1 |
| Bouchet, M | 1 |
| Rubinstenn, G | 1 |
| Maurice, T | 3 |
| Mishra, SK | 1 |
| Hidau, M | 1 |
| Rai, S | 2 |
| Huang, C | 1 |
| Su, Z | 2 |
| Guo, B | 2 |
| Wu, L | 3 |
| Chen, H | 1 |
| Ji, W | 1 |
| Wan, Y | 1 |
| Ge, RL | 1 |
| Lazzarotto, G | 1 |
| Klippel Zanona, Q | 1 |
| Cagliari Zenki, K | 1 |
| Calcagnotto, ME | 1 |
| Xiang, X | 1 |
| Xie, T | 1 |
| Mou, Y | 1 |
| Gao, Z | 2 |
| Chen, M | 1 |
| Doad, J | 1 |
| Umoh, JU | 1 |
| Norley, CJD | 1 |
| Holdsworth, DW | 1 |
| Cao, Y | 1 |
| Mak, SH | 1 |
| Zha, L | 1 |
| Han, Y | 2 |
| Man Hoi, MP | 1 |
| Shimoyama, T | 1 |
| Aoki, Y | 1 |
| Kaneda, M | 1 |
| Han, LK | 1 |
| Michihara, S | 1 |
| Takahashi, R | 1 |
| Du, F | 1 |
| Morisseau, C | 1 |
| Hammock, BD | 1 |
| Bao, X | 1 |
| Yang, H | 1 |
| Zhou, J | 1 |
| Chen, G | 1 |
| Janikova, M | 2 |
| Mainerova, K | 1 |
| Vojtechova, I | 1 |
| Petrasek, T | 1 |
| Svoboda, J | 2 |
| Stuchlik, A | 2 |
| Shuvaev, AN | 2 |
| Belozor, OS | 1 |
| Mozhei, OI | 1 |
| Khilazheva, ED | 1 |
| Fritsler, YV | 1 |
| Kasparov, S | 1 |
| Mei, Z | 1 |
| Qiu, J | 1 |
| Alcon, S | 1 |
| Hashim, J | 1 |
| Rotenberg, A | 1 |
| Meehan, WP | 1 |
| Mannix, R | 1 |
| Havolli, E | 1 |
| Hill, MD | 1 |
| Godley, A | 1 |
| Goetghebeur, PJ | 1 |
| Victorino, DB | 1 |
| Bederman, IR | 1 |
| Costa, ACS | 2 |
| Bögli, SY | 1 |
| Afthinos, M | 1 |
| Huang, MY | 1 |
| Rahman, A | 1 |
| Lamberty, Y | 1 |
| Schenker, E | 1 |
| Cella, M | 1 |
| Languille, S | 1 |
| Bordet, R | 1 |
| Richardson, J | 1 |
| Pifferi, F | 1 |
| Aujard, F | 1 |
| Kumar, A | 2 |
| Dejanovic, B | 1 |
| Hetsch, F | 1 |
| Semtner, M | 1 |
| Fusca, D | 1 |
| Arjune, S | 1 |
| Santamaria-Araujo, JA | 1 |
| Winkelmann, A | 1 |
| Ayton, S | 1 |
| Bush, AI | 1 |
| Kloppenburg, P | 1 |
| Meier, JC | 1 |
| Schwarz, G | 1 |
| Belaidi, AA | 1 |
| Tu, S | 1 |
| Akhtar, MW | 2 |
| Escorihuela, RM | 1 |
| Amador-Arjona, A | 1 |
| Swarup, V | 1 |
| Parker, J | 2 |
| Zaremba, JD | 1 |
| Holland, T | 1 |
| Bansal, N | 1 |
| Holohan, DR | 1 |
| Lopez, K | 1 |
| Ryan, SD | 1 |
| Chan, SF | 1 |
| Yan, L | 1 |
| Sultan, A | 1 |
| McKercher, SR | 2 |
| Ambasudhan, R | 2 |
| Geschwind, DH | 1 |
| Roberts, AJ | 1 |
| Terskikh, AV | 1 |
| Rissman, RA | 1 |
| Masliah, E | 1 |
| Lipton, SA | 3 |
| Nakanishi, N | 1 |
| Koola, MM | 1 |
| Dhull, DK | 1 |
| Kidana, K | 1 |
| Tatebe, T | 1 |
| Ito, K | 1 |
| Hara, N | 1 |
| Kakita, A | 1 |
| Takatori, S | 1 |
| Ouchi, Y | 2 |
| Ikeuchi, T | 1 |
| Makino, M | 2 |
| Akishita, M | 2 |
| Iwatsubo, T | 1 |
| Hori, Y | 1 |
| Tomita, T | 1 |
| Landucci, E | 1 |
| Filippi, L | 1 |
| Gerace, E | 1 |
| Catarzi, S | 1 |
| Guerrini, R | 1 |
| Pellegrini-Giampietro, DE | 1 |
| Wang, CC | 1 |
| Wee, HY | 1 |
| Hu, CY | 1 |
| Chio, CC | 1 |
| Kuo, JR | 1 |
| Ettcheto, M | 2 |
| Sánchez-López, E | 2 |
| Gómez-Mínguez, Y | 1 |
| Cabrera, H | 1 |
| Busquets, O | 1 |
| Beas-Zarate, C | 1 |
| García, ML | 2 |
| Carro, E | 1 |
| Casadesus, G | 2 |
| Auladell, C | 1 |
| Vázquez Carrera, M | 1 |
| Folch, J | 1 |
| Camins, A | 2 |
| Tanaka, A | 1 |
| Ito, Y | 2 |
| Kawasaki, H | 1 |
| Kitabayashi, C | 1 |
| Nishioka, R | 1 |
| Yamazato, M | 1 |
| Ishizawa, K | 1 |
| Nagai, T | 1 |
| Hirayama, M | 1 |
| Takahashi, K | 2 |
| Yamamoto, T | 2 |
| Araki, N | 1 |
| Egea, MA | 1 |
| Espina, M | 1 |
| Cano, A | 1 |
| Calpena, AC | 1 |
| Carmona, N | 1 |
| Silva, AM | 1 |
| Souto, EB | 1 |
| Di Curzio, DL | 1 |
| Nagra, G | 1 |
| Mao, X | 1 |
| Del Bigio, MR | 1 |
| Nakagawasai, O | 1 |
| Nemoto, W | 1 |
| Kadota, S | 1 |
| Isono, J | 1 |
| Odaira, T | 1 |
| Sakuma, W | 1 |
| Arai, Y | 1 |
| Tadano, T | 1 |
| Tan-No, K | 1 |
| Scott-McKean, JJ | 3 |
| Roque, AL | 1 |
| Surewicz, K | 1 |
| Johnson, MW | 1 |
| Surewicz, WK | 1 |
| Chang, WT | 1 |
| Puspitasari, F | 1 |
| Garcia-Miralles, M | 1 |
| Yeow, LY | 1 |
| Tay, HC | 1 |
| Koh, KB | 1 |
| Tan, LJ | 1 |
| Pouladi, MA | 1 |
| Chuang, KH | 1 |
| Kodis, EJ | 1 |
| Choi, S | 1 |
| Swanson, E | 1 |
| Ferreira, G | 1 |
| Bloom, GS | 1 |
| Mietelska-Porowska, A | 1 |
| Gasiorowska, A | 1 |
| Palasz, E | 1 |
| Koss, DJ | 1 |
| Riedel, G | 2 |
| Niewiadomska, G | 1 |
| Chung, C | 1 |
| Ha, S | 1 |
| Kang, H | 1 |
| Lee, J | 1 |
| Um, SM | 1 |
| Yan, H | 1 |
| Yoo, YE | 1 |
| Yoo, T | 1 |
| Jung, H | 1 |
| Lee, D | 1 |
| Lee, E | 1 |
| Lee, S | 1 |
| Kim, J | 2 |
| Kim, R | 1 |
| Kwon, Y | 1 |
| Kim, W | 1 |
| Kim, H | 2 |
| Duffney, L | 1 |
| Kim, D | 1 |
| Mah, W | 1 |
| Won, H | 1 |
| Mo, S | 1 |
| Kim, JY | 1 |
| Lim, CS | 1 |
| Kaang, BK | 1 |
| Boeckers, TM | 1 |
| Chung, Y | 1 |
| Jiang, YH | 1 |
| Kim, E | 1 |
| Sekar, S | 1 |
| Grandjean, J | 1 |
| Garnell, JF | 1 |
| Willems, R | 1 |
| Duytschaever, H | 1 |
| Seramani, S | 1 |
| Su, H | 1 |
| Ver Donck, L | 1 |
| Bhakoo, KK | 1 |
| Stojiljković, MP | 1 |
| Škrbić, R | 1 |
| Jokanović, M | 1 |
| Bokonjić, D | 1 |
| Kilibarda, V | 1 |
| Vulović, M | 1 |
| Kulan, H | 1 |
| Dag, T | 1 |
| Brozka, H | 1 |
| Radostova, D | 1 |
| Uribe, E | 1 |
| Fernández, L | 2 |
| Pacheco, D | 1 |
| Nayadoleni, N | 1 |
| Eblen-Zajjur, A | 1 |
| Takahashi-Ito, K | 1 |
| Murasawa, H | 1 |
| Pawlak, A | 1 |
| Kashimoto, Y | 1 |
| Kitano, Y | 1 |
| Abrahamson, EE | 1 |
| Poloyac, SM | 1 |
| Dixon, CE | 1 |
| Dekosky, ST | 1 |
| Ikonomovic, MD | 1 |
| Luo, F | 1 |
| Ju, J | 1 |
| Mak, S | 1 |
| Salih, NA | 1 |
| Al-Baggou, BK | 1 |
| Tang, S | 1 |
| Terzic, B | 1 |
| Wang, IJ | 1 |
| Sarmiento, N | 1 |
| Sizov, K | 1 |
| Takano, H | 1 |
| Marsh, ED | 1 |
| Coulter, DA | 1 |
| Atorf, J | 1 |
| Scholz, M | 1 |
| Garreis, F | 1 |
| Lehmann, J | 1 |
| Bräuer, L | 1 |
| Kremers, J | 1 |
| Hemmati, F | 1 |
| Dargahi, L | 1 |
| Nasoohi, S | 1 |
| Omidbakhsh, R | 1 |
| Mohamed, Z | 1 |
| Chik, Z | 1 |
| Naidu, M | 1 |
| Ahmadiani, A | 1 |
| Mehta, DC | 1 |
| Short, JL | 1 |
| Nicolazzo, JA | 1 |
| Finn, R | 1 |
| Kovács, AD | 2 |
| Pearce, DA | 2 |
| Ghazanfari, S | 1 |
| Imenshahidi, M | 1 |
| Etemad, L | 1 |
| Moshiri, M | 1 |
| Hosseinzadeh, H | 1 |
| Borre, YE | 1 |
| Panagaki, T | 1 |
| Koelink, PJ | 1 |
| Morgan, ME | 1 |
| Hendriksen, H | 1 |
| Garssen, J | 1 |
| Kraneveld, AD | 1 |
| Olivier, B | 1 |
| Oosting, RS | 1 |
| Yohay, K | 1 |
| Tyler, B | 1 |
| Weaver, KD | 1 |
| Pardo, AC | 1 |
| Gincel, D | 1 |
| Blakeley, J | 1 |
| Brem, H | 1 |
| Rothstein, JD | 1 |
| Tronci, E | 1 |
| Fidalgo, C | 1 |
| Zianni, E | 1 |
| Collu, M | 1 |
| Stancampiano, R | 1 |
| Morelli, M | 1 |
| Gardoni, F | 1 |
| Carta, M | 1 |
| Topdag, M | 1 |
| Topdag, DO | 1 |
| Ila, K | 1 |
| Muezzinoglu, B | 1 |
| Yaprak, B | 1 |
| Ozturk, M | 1 |
| Caliskan, S | 1 |
| Iseri, M | 1 |
| Morel, V | 1 |
| Pickering, G | 1 |
| Etienne, M | 1 |
| Dupuis, A | 1 |
| Privat, AM | 1 |
| Chalus, M | 1 |
| Eschalier, A | 1 |
| Daulhac, L | 1 |
| Abraham, R | 1 |
| Nirogi, R | 1 |
| Shinde, A | 1 |
| López-Valdés, HE | 1 |
| Clarkson, AN | 1 |
| Ao, Y | 1 |
| Charles, AC | 1 |
| Carmichael, ST | 1 |
| Sofroniew, MV | 1 |
| Brennan, KC | 1 |
| Alaux-Cantin, S | 1 |
| Buttolo, R | 1 |
| Houchi, H | 1 |
| Jeanblanc, J | 1 |
| Naassila, M | 1 |
| Gröger, M | 1 |
| Plesnila, N | 2 |
| Dhir, A | 1 |
| Chopra, K | 1 |
| Makarewicz, D | 1 |
| Sulejczak, D | 1 |
| Duszczyk, M | 1 |
| Małek, M | 1 |
| Słomka, M | 1 |
| Lazarewicz, JW | 1 |
| Smith, KL | 1 |
| Rao, RR | 1 |
| Valenza, M | 1 |
| Everitt, BJ | 1 |
| Zeiss, CJ | 1 |
| Li, WJ | 1 |
| Mao, FX | 1 |
| Chen, HJ | 1 |
| Qian, LH | 1 |
| Buzby, JS | 1 |
| He, L | 2 |
| Hong, X | 1 |
| Lamprecht, MR | 1 |
| Morrison, B | 1 |
| Ahmed, MM | 3 |
| Dhanasekaran, AR | 1 |
| Block, A | 1 |
| Tong, S | 1 |
| Costa, AC | 4 |
| Stasko, M | 1 |
| Gardiner, KJ | 2 |
| Gao, L | 1 |
| Zhao, J | 1 |
| Li, Q | 1 |
| Fan, X | 1 |
| Yin, ZQ | 1 |
| Zhao, F | 1 |
| Luo, S | 1 |
| Yue, SJ | 1 |
| Luo, Z | 1 |
| Huang, CY | 1 |
| Wang, LC | 1 |
| Shan, YS | 1 |
| Pan, CH | 1 |
| Tsai, KJ | 1 |
| Higuera, C | 1 |
| Cios, KJ | 1 |
| O'Connor, RM | 1 |
| Moloney, RD | 1 |
| Glennon, J | 1 |
| Vlachou, S | 1 |
| Cryan, JF | 1 |
| Ming, H | 1 |
| Chen, R | 1 |
| Ju, JM | 1 |
| Peng, WD | 1 |
| Zhang, GX | 1 |
| Liu, CF | 1 |
| Lee, SH | 1 |
| Kim, SH | 1 |
| Noh, YH | 1 |
| Choi, BM | 1 |
| Noh, GJ | 1 |
| Park, WD | 1 |
| Kim, EJ | 1 |
| Cho, IH | 1 |
| Bae, CS | 1 |
| Vengeliene, V | 1 |
| Olevska, A | 1 |
| Spanagel, R | 2 |
| Ota, H | 1 |
| Ogawa, S | 1 |
| Blanchard, J | 1 |
| Grundke-Iqbal, I | 1 |
| Iqbal, K | 1 |
| Sanz-Blasco, S | 1 |
| Dolatabadi, N | 1 |
| Chon, K | 1 |
| Lee, MS | 1 |
| Soussou, W | 1 |
| Nakamura, T | 1 |
| Sil, S | 1 |
| Ghosh, T | 1 |
| Ghosh, R | 1 |
| Devi, L | 1 |
| Ohno, M | 1 |
| Kim, BY | 1 |
| Bae, WY | 1 |
| Hur, DY | 1 |
| Kim, JR | 1 |
| Koh, TK | 1 |
| Lee, TH | 1 |
| Park, GB | 1 |
| Sharma, B | 1 |
| Mahfooz, K | 1 |
| Marco, S | 1 |
| Martínez-Turrillas, R | 1 |
| Raja, MK | 1 |
| Pérez-Otaño, I | 1 |
| Wesseling, JF | 1 |
| Marszalek-Grabska, M | 1 |
| Gibula-Bruzda, E | 1 |
| Jenda, M | 1 |
| Gawel, K | 1 |
| Kotlinska, JH | 1 |
| Greget, R | 1 |
| Dadak, S | 1 |
| Barbier, L | 1 |
| Lauga, F | 1 |
| Linossier-Pierre, S | 1 |
| Pernot, F | 1 |
| Legendre, A | 1 |
| Ambert, N | 1 |
| Bouteiller, JM | 1 |
| Dorandeu, F | 1 |
| Bischoff, S | 1 |
| Baudry, M | 1 |
| Fagni, L | 1 |
| Moussaoui, S | 1 |
| Bahramian, A | 1 |
| Rastegar, K | 1 |
| Namavar, MR | 1 |
| Moosavi, M | 1 |
| Kos, T | 2 |
| Aydoseli, A | 1 |
| Can, H | 1 |
| Aras, Y | 1 |
| Sabanci, PA | 1 |
| Akcakaya, MO | 1 |
| Unal, OF | 1 |
| Zhou, W | 1 |
| Zhong, G | 1 |
| Xie, H | 1 |
| Rao, X | 1 |
| Zeng, S | 1 |
| Sheng, G | 1 |
| Ji, X | 2 |
| Wu, D | 1 |
| Zou, L | 1 |
| Tortorella, M | 1 |
| Zhang, K | 2 |
| Gamdzyk, M | 1 |
| Ziembowicz, A | 1 |
| Bratek, E | 1 |
| Salinska, E | 1 |
| Ramanathan, M | 1 |
| Abdul, KK | 1 |
| Justin, A | 1 |
| Yamaki, VN | 1 |
| Wei, Z | 1 |
| Cai, X | 1 |
| Reggiani, AM | 1 |
| Simoni, E | 1 |
| Caporaso, R | 1 |
| Meunier, J | 1 |
| Keller, E | 1 |
| Rosini, M | 1 |
| Cavalli, A | 2 |
| Ishizuka, T | 1 |
| Yabuki, Y | 1 |
| Shioda, N | 1 |
| Sasaki, Y | 1 |
| Tagashira, H | 1 |
| Yawo, H | 1 |
| Yeh, JZ | 1 |
| Sakagami, H | 1 |
| Narahashi, T | 1 |
| Amidfar, M | 1 |
| Réus, GZ | 1 |
| Quevedo, J | 1 |
| Kim, YK | 1 |
| Arbabi, M | 1 |
| Caramillo, EM | 1 |
| Echevarria, DJ | 1 |
| Maciulaitiene, R | 1 |
| Pakuliene, G | 1 |
| Kaja, S | 1 |
| Pauza, DH | 1 |
| Kalesnykas, G | 1 |
| Januleviciene, I | 1 |
| Manning, SM | 1 |
| Talos, DM | 1 |
| Selip, DB | 1 |
| Park, HK | 2 |
| Park, CJ | 1 |
| Volpe, JJ | 1 |
| Jensen, FE | 1 |
| Camarasa, J | 1 |
| Marimón, JM | 1 |
| Rodrigo, T | 1 |
| Escubedo, E | 1 |
| Pubill, D | 1 |
| Cauli, O | 1 |
| Rodrigo, R | 1 |
| Boix, J | 1 |
| Piedrafita, B | 1 |
| Agusti, A | 1 |
| Felipo, V | 1 |
| Scholtzova, H | 1 |
| Wadghiri, YZ | 1 |
| Douadi, M | 1 |
| Sigurdsson, EM | 1 |
| Li, YS | 1 |
| Quartermain, D | 1 |
| Banerjee, P | 5 |
| Wisniewski, T | 1 |
| Kasatkin, DS | 1 |
| Bektaş, AO | 1 |
| Tugay, M | 1 |
| Tugay, S | 1 |
| Göçmez, SS | 1 |
| Etus, V | 1 |
| Utkan, T | 1 |
| Nakamura, S | 2 |
| Tanaka, H | 1 |
| Shimazawa, M | 1 |
| Araie, M | 1 |
| Hara, H | 1 |
| Jung, KH | 4 |
| Chu, K | 4 |
| Lee, ST | 4 |
| Kim, JH | 2 |
| Kang, KM | 1 |
| Kim, M | 4 |
| Lee, SK | 1 |
| Roh, JK | 3 |
| Chen, SR | 1 |
| Samoriski, G | 1 |
| Pan, HL | 1 |
| Danesh-Meyer, HV | 1 |
| Levin, LA | 1 |
| Lin, N | 1 |
| Wu, B | 1 |
| Qiu, Y | 1 |
| Rosi, S | 2 |
| Ramirez-Amaya, V | 2 |
| Vazdarjanova, A | 2 |
| Esparza, EE | 1 |
| Larkin, PB | 1 |
| Fike, JR | 1 |
| Wenk, GL | 3 |
| Barnes, CA | 2 |
| Wald, R | 1 |
| Dodman, N | 1 |
| Shuster, L | 1 |
| Zaja-Milatovic, S | 1 |
| Gupta, RC | 1 |
| Aschner, M | 1 |
| Milatovic, D | 1 |
| Arif, M | 2 |
| Kato, T | 4 |
| Takeda, K | 1 |
| Muramatsu, M | 1 |
| Chikuma, T | 3 |
| Nakazato, M | 1 |
| Smith, MA | 2 |
| Hay, JL | 1 |
| Kaboutari, J | 1 |
| White, JM | 1 |
| Salem, A | 1 |
| Irvine, R | 1 |
| Kamat, PK | 2 |
| Tota, S | 1 |
| Saxena, G | 1 |
| Shukla, R | 2 |
| Nath, C | 2 |
| Tabaton, M | 1 |
| Perry, G | 1 |
| Lee, HG | 1 |
| Martinez-Coria, H | 1 |
| Green, KN | 1 |
| Billings, LM | 1 |
| Kitazawa, M | 1 |
| Albrecht, M | 1 |
| Rammes, G | 1 |
| Parsons, CG | 2 |
| Gupta, S | 1 |
| LaFerla, FM | 1 |
| Ito, T | 1 |
| Nuriya, M | 1 |
| Yasui, M | 1 |
| Chen, TF | 1 |
| Huang, RF | 1 |
| Lin, SE | 1 |
| Lu, JF | 1 |
| Tang, MC | 1 |
| Chiu, MJ | 1 |
| Lockrow, J | 1 |
| Boger, H | 1 |
| Bimonte-Nelson, H | 1 |
| Granholm, AC | 1 |
| Yang, GY | 1 |
| Woo, YW | 1 |
| Park, MK | 1 |
| Bae, YC | 1 |
| Ahn, DK | 1 |
| Bonfa, E | 1 |
| Delabar, JM | 1 |
| Rueda, N | 1 |
| Llorens-Martín, M | 1 |
| Flórez, J | 1 |
| Valdizán, E | 1 |
| Trejo, JL | 1 |
| Martínez-Cué, C | 1 |
| Tai, KK | 2 |
| Truong, DD | 2 |
| Ozkürkçügil, C | 1 |
| Kömür, O | 1 |
| Ozkan, L | 1 |
| Nyakas, C | 1 |
| Granic, I | 1 |
| Halmy, LG | 1 |
| Luiten, PG | 1 |
| Bisaga, A | 1 |
| Holden, C | 1 |
| Travis, J | 1 |
| Dedeurwaerdere, S | 1 |
| Wintmolders, C | 1 |
| Straetemans, R | 1 |
| Pemberton, D | 1 |
| Langlois, X | 1 |
| Payne, RS | 1 |
| Schurr, A | 1 |
| Hougland, T | 1 |
| Lord, J | 1 |
| Herman, L | 1 |
| Lei, Z | 1 |
| El-Mallakh, RS | 1 |
| Filali, M | 1 |
| Lalonde, R | 1 |
| Rivest, S | 1 |
| Weng, SM | 1 |
| McLeod, F | 1 |
| Bailey, ME | 1 |
| Cobb, SR | 1 |
| Terry, AV | 1 |
| Callahan, PM | 1 |
| Hall, B | 1 |
| Webster, SJ | 1 |
| Quan, MN | 1 |
| Zhang, N | 1 |
| Wang, YY | 1 |
| Yiğit, U | 1 |
| Erdenöz, S | 1 |
| Uslu, U | 1 |
| Oba, E | 1 |
| Cumbul, A | 1 |
| Cağatay, H | 1 |
| Aktaş, S | 1 |
| Eskicoğlu, E | 1 |
| Abdel-Aal, RA | 1 |
| Assi, AA | 1 |
| Kostandy, BB | 1 |
| Quintanar, L | 1 |
| Montiel, T | 1 |
| Márquez, M | 1 |
| González, A | 1 |
| Massieu, L | 1 |
| Ponce-Lopez, T | 1 |
| Liy-Salmeron, G | 1 |
| Hong, E | 1 |
| Meneses, A | 1 |
| Babic, S | 1 |
| Ondrejcakova, M | 1 |
| Bakos, J | 1 |
| Racekova, E | 1 |
| Jezova, D | 1 |
| Dashniani, M | 1 |
| Burjanadze, M | 1 |
| Beselia, G | 1 |
| Chkhikvishvili, N | 1 |
| Kruashvili, L | 1 |
| Neumeister, KL | 1 |
| Riepe, MW | 1 |
| Gabelt, BT | 1 |
| Rasmussen, CA | 1 |
| Tektas, OY | 1 |
| Kim, CB | 1 |
| Peterson, JC | 1 |
| Nork, TM | 1 |
| Ver Hoeve, JN | 1 |
| Lütjen-Drecoll, E | 1 |
| Kaufman, PL | 1 |
| Romberg, C | 1 |
| McTighe, SM | 1 |
| Heath, CJ | 1 |
| Whitcomb, DJ | 1 |
| Cho, K | 1 |
| Bussey, TJ | 1 |
| Saksida, LM | 1 |
| Zimmer, ER | 1 |
| Kalinine, E | 1 |
| Haas, CB | 1 |
| Torrez, VR | 1 |
| Souza, DO | 1 |
| Muller, AP | 1 |
| Portela, LV | 1 |
| Wei, H | 1 |
| Dobkin, C | 1 |
| Sheikh, AM | 1 |
| Malik, M | 1 |
| Brown, WT | 1 |
| Milnerwood, AJ | 1 |
| Kaufman, AM | 1 |
| Sepers, MD | 1 |
| Gladding, CM | 1 |
| Fan, J | 1 |
| Coquinco, A | 1 |
| Qiao, JY | 1 |
| Lee, H | 1 |
| Wang, YT | 1 |
| Cynader, M | 1 |
| Raymond, LA | 1 |
| Saje, A | 1 |
| Wong, A | 1 |
| Ramji, S | 1 |
| Cooper, JD | 1 |
| Chen, Y | 1 |
| Evola, M | 1 |
| Young, AM | 1 |
| Busquet, P | 1 |
| Capurro, V | 1 |
| Piomelli, D | 1 |
| Reggiani, A | 1 |
| Bertorelli, R | 1 |
| Shih, AY | 1 |
| Blinder, P | 1 |
| Tsai, PS | 1 |
| Friedman, B | 1 |
| Stanley, G | 1 |
| Lyden, PD | 1 |
| Kleinfeld, D | 1 |
| Nagakura, A | 1 |
| Shitaka, Y | 1 |
| Yarimizu, J | 1 |
| Matsuoka, N | 1 |
| da Cruz, GM | 1 |
| Felipe, CF | 1 |
| Scorza, FA | 1 |
| da Costa, MA | 1 |
| Tavares, AF | 1 |
| Menezes, ML | 1 |
| de Andrade, GM | 1 |
| Leal, LK | 1 |
| Brito, GA | 1 |
| da Graça Naffah-Mazzacoratti, M | 1 |
| Cavalheiro, EA | 1 |
| de Barros Viana, GS | 1 |
| Kilic, U | 1 |
| Yilmaz, B | 1 |
| Reiter, RJ | 1 |
| Yüksel, A | 1 |
| Kilic, E | 1 |
| Schuettauf, F | 1 |
| Quinto, K | 1 |
| Naskar, R | 1 |
| Zurakowski, D | 1 |
| Rukoyatkina, NI | 1 |
| Gorbunova, LV | 1 |
| Gmiro, VE | 1 |
| Lukomskaya, NY | 1 |
| Talalaenko, AN | 2 |
| Pankrat'ev, DV | 2 |
| Goncharenko, NV | 1 |
| Block, F | 1 |
| Habermeyer, B | 1 |
| Nisijima, K | 1 |
| Shioda, K | 1 |
| Yoshino, T | 1 |
| Takano, K | 1 |
| Kato, S | 1 |
| Culmsee, C | 1 |
| Junker, V | 1 |
| Kremers, W | 1 |
| Thal, S | 1 |
| Krieglstein, J | 1 |
| McGann-Gramling, K | 1 |
| Hauss-Wegrzyniak, B | 1 |
| Hong-Ju, Y | 1 |
| Wei-Guo, S | 1 |
| Nan, Z | 1 |
| Wei-Xiu, Y | 1 |
| Zhong-Wei, J | 1 |
| Jun-Wei, W | 1 |
| Zheng-Hua, G | 1 |
| Bo-Hua, Z | 1 |
| Zhi-Pu, L | 1 |
| Zhe-Hui, G | 1 |
| Hoshino, H | 1 |
| Yamada, M | 1 |
| Hare, WA | 2 |
| WoldeMussie, E | 2 |
| Lai, RK | 1 |
| Ton, H | 2 |
| Ruiz, G | 2 |
| Chun, T | 1 |
| Wheeler, L | 2 |
| Weinreb, RN | 2 |
| Wijono, M | 1 |
| Feldmann, B | 1 |
| Zangwill, L | 1 |
| Pud, D | 1 |
| Eisenberg, E | 2 |
| Van Dam, D | 2 |
| Abramowski, D | 1 |
| Staufenbiel, M | 1 |
| De Deyn, PP | 2 |
| Higuchi, M | 1 |
| Iwata, N | 1 |
| Matsuba, Y | 1 |
| Sato, K | 1 |
| Sasamoto, K | 1 |
| Ozsüer, H | 1 |
| Görgülü, A | 2 |
| Kiriş, T | 1 |
| Cobanoğlu, S | 1 |
| Sinn, DI | 2 |
| Ko, SY | 2 |
| Zhang, D | 1 |
| Almeida, RC | 1 |
| Felisbino, CS | 1 |
| López, MG | 1 |
| Rodrigues, AL | 1 |
| Gabilan, NH | 1 |
| Yücel, YH | 1 |
| Gupta, N | 1 |
| Mizisin, AP | 1 |
| Kalichman, MW | 1 |
| Creeley, C | 1 |
| Wozniak, DF | 1 |
| Labruyere, J | 1 |
| Taylor, GT | 1 |
| Olney, JW | 1 |
| Lapchak, PA | 1 |
| Bell, KF | 1 |
| Claudio Cuello, A | 1 |
| Murayama, N | 1 |
| Noshita, T | 1 |
| Katsuragi, R | 1 |
| Ohno, T | 1 |
| Park, JE | 1 |
| Kang, L | 1 |
| Worley, PF | 1 |
| Song, EC | 1 |
| Kim, JM | 1 |
| Park, DK | 1 |
| Zhong, L | 1 |
| Bradley, J | 1 |
| Schubert, W | 1 |
| Ahmed, E | 1 |
| Adamis, AP | 1 |
| Shima, DT | 1 |
| Robinson, GS | 1 |
| Ng, YS | 1 |
| Back, T | 1 |
| Otto, D | 1 |
| Kittner, D | 1 |
| Schüler, OG | 1 |
| Hennerici, MG | 1 |
| Mennel, HD | 1 |
| Belmin, J | 1 |
| Péquignot, R | 1 |
| Konrat, C | 1 |
| Pariel-Madjlessi, S | 1 |
| Stasko, MR | 1 |
| Gil, DW | 1 |
| Cheevers, CV | 1 |
| Donello, JE | 1 |
| Lee, NY | 1 |
| Jung, SW | 1 |
| Park, CK | 1 |
| Meisner, F | 1 |
| Scheller, C | 1 |
| Kneitz, S | 1 |
| Sopper, S | 1 |
| Neuen-Jacob, E | 1 |
| Riederer, P | 1 |
| ter Meulen, V | 1 |
| Koutsilieri, E | 1 |
| Drever, BD | 1 |
| Anderson, WG | 1 |
| Johnson, H | 1 |
| O'Callaghan, M | 1 |
| Seo, S | 1 |
| Choi, DY | 1 |
| Platt, B | 1 |
| Sencer, A | 1 |
| Arica, O | 1 |
| Kirin, T | 1 |
| Aktan, D | 1 |
| Muehlmann, AM | 1 |
| Devine, DP | 1 |
| Dong, H | 1 |
| Yuede, CM | 1 |
| Coughlan, C | 1 |
| Lewis, B | 1 |
| Csernansky, JG | 1 |
| LaCross, S | 1 |
| Strassman, AM | 1 |
| Vogels, BA | 1 |
| Maas, MA | 1 |
| Daalhuisen, J | 1 |
| Quack, G | 2 |
| Chamuleau, RA | 1 |
| Lagrèze, WA | 2 |
| Knörle, R | 1 |
| Bach, M | 1 |
| Feuerstein, TJ | 1 |
| Piasecki, J | 1 |
| Koros, E | 1 |
| Dyr, W | 1 |
| Kostowski, W | 1 |
| Danysz, W | 2 |
| Bienkowski, P | 1 |
| Ehrlich, M | 1 |
| Knolle, E | 1 |
| Ciovica, R | 1 |
| Böck, P | 1 |
| Turkof, E | 1 |
| Grabenwöger, M | 1 |
| Cartes-Zumelzu, F | 1 |
| Kocher, A | 1 |
| Pockberger, H | 1 |
| Fang, WC | 1 |
| Wolner, E | 1 |
| Havel, M | 1 |
| Kornhuber, J | 1 |
| Stieg, PE | 1 |
| Sathi, S | 1 |
| Warach, S | 1 |
| Le, DA | 1 |
| Miyamoto, TA | 1 |
| Miyamoto, KJ | 1 |
| Kawase, C | 1 |
| Matsubara, M | 1 |
| Kawase, K | 1 |
| Sawada, A | 1 |
| Kitazawa, Y | 1 |
| Gordienko, DV | 1 |
| Zinkovich, II | 1 |
| Krivobok, GK | 1 |
| Grehn, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Amantadine for Neuroenhancement in Acute Patients Study - A Prospective Pilot Proof of Concept Phase IIb Study in Intensive and Intermediate Care Unit Patients[NCT05479032] | Phase 2 | 50 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down Syndrome[NCT02304302] | Phase 2 | 160 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment[NCT01876823] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Pilot Study of Memantine for Enhanced Stroke Recovery[NCT02144584] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2014-01-31 | Active, not recruiting | ||
| Memantine for Refractory OCD Patients: a Pragmatic Double Blind, Randomized, Parallel Group, Placebo Controlled, Monocentric Trial[NCT05015595] | Phase 3 | 20 participants (Anticipated) | Interventional | 2021-09-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This is a measure of adaptive functioning that integrates information from 13 different domains (e.g., gross motor, social interaction, eating, toileting, dressing, personal self-care, etc.). It is in a questionnaire format, which a caregiver can complete while the participant is being tested. Standard scores for all indices will be derived from age norms that extend from birth to age 80, as these were used as dependent variables. We report here on the Broad Independence Score recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the SIB-R Score Scale in this study was -24 (this number is below 0 because -24 was the minimum value for the worst performing participant in the trial) and the maximum value of this scale is 153; higher scores mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 6.88 |
| Memantine | 3.23 |
The primary efficacy measure is focused on episodic memory. The CVLT-II short form assesses supraspan word learning ability as an index of episodic verbal long-term memory. We hypothesize that treatment with memantine will produce significant improvements in this test. The main dependent variable selected, based on prior literature was the total number of target items correct summed across learning trials 1-4. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). Scale Range: from 0 to 36; higher scores represent better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 3.3 |
| Memantine | 3.49 |
This is a measure of non-verbal memory that requires the participant to learn associations between an abstract visual pattern and its location. Two dependent variables have been selected: Total number of items correct on the first trial of each stage, and total number of stages completed. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the PAL Memory Score Scale is 0 and the maximum value is 21; higher scores mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 1 |
| Memantine | 0.67 |
This is a measure of non-verbal memory. Total number correct across the two series of items presented was used as the dependent variable. We used the PRM total scale in this study, which represents the sum of the PRM correct scores (ranging from 0 to 24) and the PRM delayed scores (ranging from 0 to 24). Therefore, the range of the PRM total scale is from 0 to 48; higher values mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 0.45 |
| Memantine | -0.05 |
This is a measure of rote short-term verbal memory. Total number of items correct were used as the dependent variable. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value for this scale is 0 and the maximum value is 38; higher scores mean a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 0.03 |
| Memantine | -0.01 |
This measure is a computerized version of the Corsi Blocks task, a long-standing neuropsychological test. The main dependent variables selected for this test was the span length, which is the longest sequence of numbers recalled accurately. The minimum value of the Spatial Span Length Score Scale is 0 and the maximum value is 9; higher scores mean better outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 0.13 |
| Memantine | 0.03 |
"The test requires participants to search under a series of colored boxes to locate a blue token hidden underneath one of them. During a series of trials, the participant is told that the token will be in a new location each time and that they should not go back to a location he or she has looked in previously. The main dependent variable was the total number of errors (between errors), which indexes the number of times a participant went back to a box where a token had already been found, lower scores mean better performance. The minimum value of the Spatial Working Memory scale is 0 and the maximum value is 137 (which was computed as the equivalent to -4 standard deviations from the mean of this measure); higher scores mean worse outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2)." (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | -0.09 |
| Memantine | -1.4 |
"This is a measure of inhibitory control, often used as a marker for prefrontal-striatal function integrity. Specifically, it measures the participant's ability to inhibit pre-potent behavioral responses that have been established by provision of prior go or no-go cues in a classical conditioning paradigm. The main dependent variables selected was speed of response of execution to Go targets. The minimum value of the speed of response of execution to Go targets is 280 milliseconds (ms) and the maximum value is 1000 ms; higher scores mean worse outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2)." (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | ms (Mean) |
|---|---|
| Placebo | -2.52 |
| Memantine | 0.22 |
This test provides a measure of non-verbal reasoning ability that requires subjects to visually inspect a matrix of 4 or 9 pictures that has a missing piece. Participants have to infer a rule or pattern in the stimuli and select the appropriate response from a range of 4-6 possibilities. Since age norms are not available for individuals older than 17y11m, the ability score will be used as the dependent variable. This is an intermediate score based on Rasch modeling that corrects for different items set being administered to participants. The minimum value of the DAS-II Rasch Score Scale is 0 and the maximum value is 153; higher scores mean better outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 0.75 |
| Memantine | 2.66 |
This is a measure of receptive semantics, whereby the participant is asked to point to a picture (out of 4) that corresponds to a word spoken by the examiner. As this test has a 0.85 correlation with composite measures of Verbal IQ (i.e. from the Wechsler Intelligence Scale series), it can be used in conjunction with the Matrices subtest to estimate overall intellectual functioning. The total number of items correct was used as the dependent variable, following the administration manual's rules for basals and ceilings. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value for this scale is 0 and the maximum value is 192, higher scores mean a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 4.46 |
| Memantine | 5.63 |
This is a measure of receptive syntax skills (Bishop, 1983). Participants are asked to point to a picture (out of 4) that corresponds to a phrase or sentence spoken by the examiner. The total number of items correct (rather than blocks passed) will be used as the dependent variable, following the administration manual's ceiling rule. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the scores is 0 and the maximum value is 40; with higher scores considered to be a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 0.49 |
| Memantine | 0.89 |
Incidence of adverse events was monitored by clinical history, physical examinations, electrocardiograms (ECGs), clinical laboratory tests, the Screen for Childhood Anxiety Related Emotional Disorders (SCARED). Here, we report the analysis of the effect of memantine treatment on QTc intervals because of its clinical importance for this analysis for potential drug toxicity. QTc intervals ≥ 450 ms are generally considered long, and drug-induced QTc interval prolongations ≥ 60 ms are generally considered clinically relevant. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | ms (Mean) |
|---|---|
| Placebo | -1.30 |
| Memantine | -0.11 |
Change in 24-item Hamilton Rating Scale for Depression (HAMD) scores from baseline to Week 48: HAMD measures depression severity based on a series of 24 items items. The range of HAMD total score is 0-74; 0 indicates no depressive symptoms and a maximum HAMD score is a 74, where the greater the score indicates more significant psychopathology. In this study, moderate to severe depression is considered a HAMD-24 greater than 14. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | scores on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -15.2 |
Change in Selective Reminding Test-Delayed Recall scores from baseline to Week 48: SRT Delay is administered 15 minutes after the immediate recall portion. Patients are asked to remember as many of the words as they can from the 6 trials. Maximum raw score is a 12 for free recall. If a patient is unable to recall a word, they are given a chance to recognize it among three incorrect word choices. Maximum raw score for recognition is 12. The greater the score on the delayed recall portion, the better the patient does on the assessment. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.2 |
Change in Selective Reminding Test-Total Immediate Recall (SRT-IR) scores from baseline to Week 48: Measures word recall (maximum 12 words per trial, across 6 trials). Maximum total recall score across 6 trials is 72; minimum recall is 0 across 6 trials. The higher the raw score, the better the patient did at recalling the target words. The unit of measure is the raw score, or the sum of the number of words recalled across all 6 trials. (NCT01876823)
Timeframe: baseline, 48 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 7.5 |
Change in Trails A scores from baseline to Week 48: Measures attention and executive function. It asks patients to connect numbers from 1-25 in numerical order as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.9 |
Change from baseline to Week 48 on Trails B: Measures attention and executive function. It asks patients to connect numbers and letters in numerical to alphabetical order from (1-13 and A-L) as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers and letters, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -36.3 |
Change in Wechsler Memory Scale-III scores from baseline to Week 48: The WMS-III Visual Reproduction sub-test was used to measure visual working memory and delayed memory. Patients were shown pictures of four drawings and were asked to reproduce them from memory immediately after seeing them, and 25 minutes after seeing them. The four scores are summed and the greater the total raw score, the better the patient did on the assessment. The maximum raw score for this test is a 41 on both the immediate and delayed portions (the overall range is 0-82 points). The change score is calculated using the total scores of both the immediate and delayed portions. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 9.9 |
The CDR is a numeric rating scale that is used to quantify the severity of one's cognitive function. The scale goes from 0=normal; 0.5=mild cognitive impairment; 1 to 3=mild to moderate/severe dementia. CDR was used a dichotomous outcome measure (no=0; yes=1). (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) |
|---|---|
| Es-citalopram and Memantine Treatment | 1 |
The CGI Cognitive Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses from the entire group were calculated. Mean at final visit and baseline is reported below. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| CGI-Cognitive Change (Baseline) | Clinical Global Impression-Cogntive Change (WK 48) | |
| Es-citalopram and Memantine Treatment | 3.6 | 2.7 |
The CGI Depression Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses were calculated for the entire group. Mean at final visit has been reported below. Higher mean at baseline indicates a decrease in depression scores. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Cognitive Global Impression at Baseline | Cognitive Global Impression at Final Visit (WK 48) | |
| Es-citalopram and Memantine Treatment | 4.1 | 2.1 |
"Somatic side effect rating scale which includes 26 common somatic side effects associated with previous medication clinical trials; rated by the study physician. Factors were dichotomized to yes or no responses on this scale, which equated to the symptom being either present or not present. Yes and no responses were given a value of 0 (no) or 1 (yes). Responses from the entire group were calculated and the mean at baseline and the last visit is reported below." (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Treatment Emergent Side Effects (Baseline) | Treatment Emergent Side Effects (WK 48) | |
| Es-citalopram and Memantine Treatment | 6.6 | 3.2 |
12 reviews available for memantine and Disease Models, Animal
| Article | Year |
|---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Improving the predictive value of interventional animal models data.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Data Mining; Databases, Factual; Disease Mode | 2015 |
Alzheimer's disease in the zebrafish: where can we take it?
Topics: Alzheimer Disease; Animals; Dementia; Disease Models, Animal; Donepezil; Humans; Indans; Memantine; | 2017 |
Neuroprotection: extrapolating from neurologic diseases to the eye.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Endpoint Determination; Excitatory Amino | 2009 |
[New perspectives on molecular and genic therapies in Down syndrome].
Topics: Animals; Catechin; Chromosomes, Human, Pair 21; Disease Models, Animal; Down Syndrome; Droxidopa; Dr | 2010 |
Alzheimer's disease and age-related memory decline (preclinical).
Topics: Aging; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Histamine H3 A | 2011 |
On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Down Syndrome; Excitatory Amino Acid Antagonis | 2011 |
[Glutamate antagonists for treatment of neuropathic pain].
Topics: Amantadine; Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Humans; Ketamine; Me | 2003 |
[NMDA receptor antagonists: a new treatment for neuropathic pain].
Topics: Animals; Clinical Trials as Topic; Dextromethorphan; Disease Models, Animal; Excitatory Amino Acid A | 1999 |
Altered synaptic function in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Humans; Memantine; Mice; | 2006 |
[Management of Alzheimer disease].
Topics: Aged; Alzheimer Disease; Animals; Antipsychotic Agents; Caregivers; Case Management; Cholinesterase | 2007 |
Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.
Topics: Animals; Brain; Disease Models, Animal; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagoni | 1999 |
Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.
Topics: Animals; Brain; Disease Models, Animal; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagoni | 1999 |
Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.
Topics: Animals; Brain; Disease Models, Animal; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagoni | 1999 |
Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.
Topics: Animals; Brain; Disease Models, Animal; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagoni | 1999 |
2 trials available for memantine and Disease Models, Animal
| Article | Year |
|---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Memantine enhances recovery from stroke.
Topics: Animals; Behavior, Animal; Cerebral Cortex; Cerebral Infarction; Disease Models, Animal; Excitatory | 2014 |
228 other studies available for memantine and Disease Models, Animal
| Article | Year |
|---|---|
In vitro and in vivo evaluation of polymethylene tetraamine derivatives as NMDA receptor channel blockers.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Memantine; Mice; Mol | 2013 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Behavior, Animal; Binding Sites; Ce | 2020 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Recepto | 2022 |
Astrocytic Kir4.1 regulates NMDAR/calpain signaling axis in lipopolysaccharide-induced depression-like behaviors in mice.
Topics: Animals; Antidepressive Agents; Astrocytes; Behavior, Animal; Calpain; Depression; Disease Models, A | 2021 |
Effect of memantine on the survival of an ischemic random skin flap and the underlying mechanism.
Topics: Angiogenesis Inducing Agents; Animals; Anti-Inflammatory Agents; Antioxidants; Disease Models, Anima | 2021 |
Effects of Memantine and High Dose Vitamin D on Gait in Male APP/PS1 Alzheimer's Disease Mice Following Vitamin D Deprivation.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Gait Analysis; Male; Memantine; Mice; Mice, Tran | 2022 |
Memantine treatment does not affect compulsive behavior or frontostriatal connectivity in an adolescent rat model for quinpirole-induced compulsive checking behavior.
Topics: Animals; Compulsive Behavior; Disease Models, Animal; Dopamine Agonists; Memantine; Obsessive-Compul | 2022 |
Propolis Promotes Memantine-Dependent Rescue of Cognitive Deficits in APP-KI Mice.
Topics: Adenosine Triphosphate; Alzheimer Disease; Animals; Calcium; Calcium-Calmodulin-Dependent Protein Ki | 2022 |
Hypoxic and Hypercapnic Responses in Transgenic Murine Model of Alzheimer's Disease Overexpressing Human AβPP: The Effects of Pretreatment with Memantine and Rivastigmine.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Disease Models, Animal; Humans; Hypercapnia; Hypox | 2022 |
Pharmacological Modulation of Glutamatergic and Neuroinflammatory Pathways in a Lafora Disease Mouse Model.
Topics: Adolescent; Animals; Disease Models, Animal; Dual-Specificity Phosphatases; Humans; Lafora Disease; | 2022 |
Glial cell reactivity and oxidative stress prevention in Alzheimer's disease mice model by an optimized NMDA receptor antagonist.
Topics: Alzheimer Disease; Animals; Arginase; Brain-Derived Neurotrophic Factor; Calcineurin; Calcium; Chiti | 2022 |
Does memantine show chemopreventive effect against mice 4T1 breast tumor model?
Topics: Animals; Disease Models, Animal; Female; Injections, Intraperitoneal; Interleukin-6; Memantine; Mice | 2022 |
Memantine/Aripiprazole Combination Alleviates Cognitive Dysfunction in Valproic Acid Rat Model of Autism: Hippocampal CREB/BDNF Signaling and Glutamate Homeostasis.
Topics: Animals; Aripiprazole; Autism Spectrum Disorder; Autistic Disorder; Brain-Derived Neurotrophic Facto | 2023 |
Edaravone Improves Streptozotocin-Induced Memory Impairment via Alleviation of Behavioral Dysfunction, Oxidative Stress, Inflammation, and Histopathological Parameters.
Topics: Alzheimer Disease; Animals; Antioxidants; Disease Models, Animal; Donepezil; Edaravone; Inflammation | 2023 |
Effects of thymoquinone and memantine alone and in combination on memory and hippocampal morphology in rats with streptozotocin-induced Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Hippocampus; Male; Maze Learning; Memantine; Neu | 2023 |
Effects of the drug combination memantine and melatonin on impaired memory and brain neuronal deficits in an amyloid-predominant mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cholineste | 2019 |
Lactoferrin Coupled Lower Generation PAMAM Dendrimers for Brain Targeted Delivery of Memantine in Aluminum-Chloride-Induced Alzheimer's Disease in Mice.
Topics: Aluminum Chloride; Alzheimer Disease; Animals; Brain; Cognition; Dendrimers; Disease Models, Animal; | 2019 |
Gamma radiation preparation of chitosan nanoparticles for controlled delivery of memantine.
Topics: Acetic Acid; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antiparkinson Agents; Brain; Chitosa | 2020 |
Concomitant memantine and
Topics: Alzheimer Disease; Animals; Animals, Genetically Modified; Biomarkers; Choline; Cognitive Dysfunctio | 2020 |
The pharmacokinetic parameters and the effect of a single and repeated doses of memantine on gastric myoelectric activity in experimental pigs.
Topics: Administration, Oral; Alzheimer Disease; Animals; Disease Models, Animal; Electromyography; Excitato | 2020 |
Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors enhance procognitive effects of conventional anti-Alzheimer drugs in scopolamine-treated rats.
Topics: Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Choliner | 2020 |
Withdrawal from Extended, Intermittent Access to A Highly Palatable Diet Impairs Hippocampal Memory Function and Neurogenesis: Effects of Memantine.
Topics: Animals; Behavior, Animal; Body Weight; Diet; Disease Models, Animal; Eating; Feeding and Eating Dis | 2020 |
Modelling and treating GRIN2A developmental and epileptic encephalopathy in mice.
Topics: Animals; Dextromethorphan; Disease Models, Animal; Epilepsy, Generalized; Excitatory Amino Acid Anta | 2020 |
Effect of memantine on expression of Bace1-as and Bace1 genes in STZ-induced Alzheimeric rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Antiparkins | 2020 |
Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders.
Topics: Animals; Apoptosis; Aquaporin 4; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; | 2020 |
Delayed Adjunctive Treatment of Organophosphate-Induced Status Epilepticus in Rats with Phenobarbital, Memantine, or Dexmedetomidine.
Topics: Animals; Anticonvulsants; Brain; Cell Death; Dexmedetomidine; Disease Models, Animal; Dose-Response | 2020 |
Chronic Memantine Treatment Ameliorates Behavioral Deficits, Neuron Loss, and Impaired Neurogenesis in a Model of Alzheimer's Disease.
Topics: Administration, Oral; Alzheimer Disease; Animals; Anxiety; Behavior, Animal; CA1 Region, Hippocampal | 2021 |
Memantine effects on ingestion microstructure and the effect of administration time: A within-subject study.
Topics: Animals; Conditioning, Classical; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking | 2020 |
Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Behavior, Animal; Disease Models, Animal | 2021 |
Memantine and Ibuprofen pretreatment exerts anti-inflammatory effect against streptozotocin-induced astroglial inflammation via modulation of NMDA receptor-associated downstream calcium ion signaling.
Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Calcium; Calcium Signaling; Cell Line, Tumor; Disease | 2021 |
Antitumorigenic Effect of Memantine via Interfering Glutamate Metabolism in Mouse 4T1 Breast Tumor Model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Drug S | 2021 |
The Tetramethylpyrazine Analogue T-006 Alleviates Cognitive Deficits by Inhibition of Tau Expression and Phosphorylation in Transgenic Mice Modeling Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Autophagy; Autophagy-Related Protein-1 H | 2021 |
Memantine ameliorates cognitive impairment induced by exposure to chronic hypoxia environment at high altitude by inhibiting excitotoxicity.
Topics: Altitude; Altitude Sickness; Alzheimer Disease; Animals; Cell Death; Cognition; Cognitive Dysfunctio | 2021 |
Effect of Memantine on Pentylenetetrazol-induced Seizures and EEG Profile in Animal Model of Cortical Malformation.
Topics: Animals; Disease Models, Animal; Electroencephalography; Male; Memantine; Pentylenetetrazole; Rats; | 2021 |
Memantine protects blood-brain barrier integrity and attenuates neurological deficits through inhibiting nitric oxide synthase ser1412 phosphorylation in intracerebral hemorrhage rats: involvement of peroxynitrite-related matrix metalloproteinase-9/NLRP3
Topics: Animals; Blood-Brain Barrier; Brain Edema; Cerebral Hemorrhage; Collagenases; Disease Models, Animal | 2021 |
Effect of Memantine Treatment and Combination with Vitamin D Supplementation on Body Composition in the APP/PS1 Mouse Model of Alzheimer's Disease Following Chronic Vitamin D Deficiency.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Body Composition; Dietary Supplements; D | 2021 |
Therapeutic efficacy of novel memantine nitrate MN-08 in animal models of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Memantine; Mice; Mice, Transgenic | 2021 |
[Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment].
Topics: Administration, Oral; Alzheimer Disease; Animals; Disease Models, Animal; Dizziness; Drug Therapy, C | 2021 |
Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis.
Topics: Animals; Binding Sites; Catalytic Domain; Disease Models, Animal; Drug Design; Enzyme Inhibitors; Ep | 2021 |
Memantine and Riluzole Exacerbate, Rather Than Ameliorate Behavioral Deficits Induced by 8-OH-DPAT Sensitization in a Spatial Task.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Disease Models, Animal; Male; Mem | 2021 |
Protective Effect of Memantine on Bergmann Glia and Purkinje Cells Morphology in Optogenetic Model of Neurodegeneration in Mice.
Topics: Animals; Disease Models, Animal; Dopamine Agents; Memantine; Mice; Neurodegenerative Diseases; Neuro | 2021 |
Memantine improves outcomes after repetitive traumatic brain injury.
Topics: Animals; Behavior, Animal; Brain Concussion; Cerebral Cortex; Disease Models, Animal; Excitatory Ami | 2018 |
Spatial recognition test: A novel cognition task for assessing topographical memory in mice.
Topics: Alzheimer Disease; Animals; Cognition; Disease Models, Animal; Donepezil; Indans; Levetiracetam; Mal | 2017 |
Pharmacokinetic Properties of Memantine after a Single Intraperitoneal Administration and Multiple Oral Doses in Euploid Mice and in the Ts65Dn Mouse Model of Down's Syndrome.
Topics: Administration, Oral; Animals; Brain; Disease Models, Animal; Down Syndrome; Excitatory Amino Acid A | 2017 |
Effect of Gabapentin/Memantine on the Infantile Nystagmus Syndrome in the Zebrafish Model: Implications for the Therapy of Ocular Motor Diseases.
Topics: Amines; Animals; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Disease Models, Animal; Exci | 2017 |
Effects of acute administration of donepezil or memantine on sleep-deprivation-induced spatial memory deficit in young and aged non-human primate grey mouse lemurs (Microcebus murinus).
Topics: Aging; Alzheimer Disease; Animals; Cheirogaleidae; Disease Models, Animal; Donepezil; Indans; Male; | 2017 |
S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency.
Topics: Animals; Calcium Signaling; Cysteine; Disease Models, Animal; GABAergic Neurons; HEK293 Cells; Human | 2017 |
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Biomarkers; Brain; Cell Death; Disease Models, Animal; | 2017 |
Galantamine and memantine combination for cognition: Enough or more than enough to translate from murines and macaques to men with schizophrenia?
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Galantamine; Humans; Memantine; Neurotra | 2019 |
Tramadol ameliorates behavioural, biochemical, mitochondrial and histological alterations in ICV-STZ-induced sporadic dementia of Alzheimer's type in rats.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Dementia; Disease Models, Animal; Dose-Response Relati | 2018 |
Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Astrocytes; Brain; Cell Line, Tumor; Cul | 2018 |
Neuroprotective effects of topiramate and memantine in combination with hypothermia in hypoxic-ischemic brain injury in vitro and in vivo.
Topics: Animals; Animals, Newborn; Combined Modality Therapy; Disease Models, Animal; Fructose; Hypothermia, | 2018 |
The Effects of Memantine on Glutamic Receptor-Associated Nitrosative Stress in a Traumatic Brain Injury Rat Model.
Topics: Animals; Apoptosis; Brain Injuries, Traumatic; Disease Models, Animal; Male; Memantine; Neuroprotect | 2018 |
Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Body Weight; Cognition; Diet, High-Fat; Disease M | 2018 |
Effects of Memantine on Nitric Oxide Production and Hydroxyl Radical Metabolism during Cerebral Ischemia and Reperfusion in Mice.
Topics: Animals; Antioxidants; Biomarkers; Blood Flow Velocity; Brain Ischemia; CA1 Region, Hippocampal; Cer | 2018 |
Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antiparkinson Agents; Astro | 2018 |
Memantine treatment of juvenile rats with kaolin-induced hydrocephalus.
Topics: Animals; Body Weight; Cerebral Ventricles; Disease Models, Animal; Excitatory Amino Acid Antagonists | 2018 |
Memantine ameliorates depressive-like behaviors by regulating hippocampal cell proliferation and neuroprotection in olfactory bulbectomized mice.
Topics: Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Cell Proliferation; Cyclic AMP Response Eleme | 2018 |
Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome.
Topics: Amyloid beta-Peptides; Animals; CA1 Region, Hippocampal; Disease Models, Animal; Down Syndrome; Elec | 2018 |
Connectomic imaging reveals Huntington-related pathological and pharmaceutical effects in a mouse model.
Topics: Animals; Axons; Behavior, Animal; Cognition; Connectome; Disease Models, Animal; Electric Stimulatio | 2018 |
N-methyl-D-aspartate receptor-mediated calcium influx connects amyloid-β oligomers to ectopic neuronal cell cycle reentry in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Calcium; Cell Cycle; Cells, Cultured; Disease Mod | 2018 |
Pore-former enabled seeding of tau in rats: Alleviation by memantine and lithium chloride.
Topics: Alzheimer Disease; Animals; CA1 Region, Hippocampal; Disease Models, Animal; Lithium Chloride; Male; | 2019 |
Early Correction of N-Methyl-D-Aspartate Receptor Function Improves Autistic-like Social Behaviors in Adult Shank2
Topics: Age Factors; Animals; Autism Spectrum Disorder; Behavior, Animal; Disease Models, Animal; Excitatory | 2019 |
Neuro-metabolite profiles of rodent models of psychiatric dysfunctions characterised by MR spectroscopy.
Topics: Anhedonia; Animals; Choline; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; | 2019 |
Prophylactic potential of memantine against soman poisoning in rats.
Topics: Acetylcholinesterase; Animals; Antidotes; Atropine; Behavior, Animal; Chemical Warfare Agents; Choli | 2019 |
In silico identification of critical proteins associated with learning process and immune system for Down syndrome.
Topics: Animals; Bayes Theorem; Computer Simulation; Disease Models, Animal; Down Syndrome; Gene Expression; | 2019 |
No effect of riluzole and memantine on learning deficit following quinpirole sensitization - An animal model of obsessive-compulsive disorder.
Topics: Animals; Behavior, Animal; Cognition; Disease Models, Animal; Dopamine Agonists; Excitatory Amino Ac | 2019 |
Administration of memantine reverses behavioral, histological, and electrophysiological abnormalities in rats subjected to early maternal deprivation.
Topics: Animals; Animals, Newborn; Auditory Cortex; Behavior, Animal; Cognitive Dysfunction; Corpus Striatum | 2019 |
Memantine ameliorates learning and memory disturbance and the behavioral and psychological symptoms of dementia in thiamine-deficient mice.
Topics: Administration, Oral; Animals; Anxiety; Behavior, Animal; Biogenic Monoamines; Body Weight; Dementia | 2019 |
Acute and chronic effects of single dose memantine after controlled cortical impact injury in adult rats.
Topics: Animals; Behavior, Animal; Brain Injuries, Traumatic; Cerebral Cortex; Disease Models, Animal; Excit | 2019 |
The dual-functional memantine nitrate MN-08 alleviates cerebral vasospasm and brain injury in experimental subarachnoid haemorrhage models.
Topics: Animals; Brain Injuries; Disease Models, Animal; Dose-Response Relationship, Drug; HEK293 Cells; Hum | 2019 |
Effect of memantine hydrochloride on cisplatin-induced neurobehavioral toxicity in mice.
Topics: Animals; Antineoplastic Agents; Behavior, Animal; Cisplatin; Disease Models, Animal; Excitatory Amin | 2020 |
Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.
Topics: Animals; Behavior, Animal; Codon, Nonsense; Disease Models, Animal; Epileptic Syndromes; Excitatory | 2019 |
Functional protective effects of long-term memantine treatment in the DBA/2J mouse.
Topics: Animals; Disease Models, Animal; Dopamine Agents; Electroretinography; Female; Follow-Up Studies; Gl | 2013 |
Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: comparison with memantine.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Avoidance Learning; Cytokines; Disease Models, An | 2013 |
Reduced CNS exposure of memantine in a triple transgenic mouse model of Alzheimer's disease assessed using a novel LC-MS technique.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Brain; Chromatography, Liquid; Disease Models, Anim | 2013 |
Treatment of the Ppt1(-/-) mouse model of infantile neuronal ceroid lipofuscinosis with the N-methyl-D-aspartate (NMDA) receptor antagonist memantine.
Topics: Animals; Disease Models, Animal; Disease Progression; Excitatory Amino Acid Antagonists; Memantine; | 2013 |
Effect of cyanocobalamin (vitamin B12) in the induction and expression of morphine tolerance and dependence in mice.
Topics: Analgesics, Opioid; Animals; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Dr | 2014 |
Neuroprotective and cognitive enhancing effects of a multi-targeted food intervention in an animal model of neurodegeneration and depression.
Topics: Animals; Atrophy; Cell Death; Cognition Disorders; Depressive Disorder; Disease Models, Animal; Hipp | 2014 |
Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Delivery Systems; Excitator | 2014 |
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Excitatory Amino Aci | 2014 |
The effect of memantine on functional recovery of the facial nerve after crush injury.
Topics: Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Facial Injuries; Facial Nerve; F | 2015 |
Low doses of dextromethorphan have a beneficial effect in the treatment of neuropathic pain.
Topics: Animals; Cognition; Dextromethorphan; Disease Models, Animal; Dose-Response Relationship, Drug; Exci | 2014 |
Role of glutamate and advantages of combining memantine with a 5HT6 ligand in a model of depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Glutamic Acid; | 2014 |
Memantine reduces alcohol drinking but not relapse in alcohol-dependent rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Conditioning, Operant; Disease Models, Animal; Dose-Response | 2015 |
The neuroprotective effect of 17β-estradiol is independent of its antioxidative properties.
Topics: Animals; Antioxidants; Body Weight; Brain; Brain Infarction; Cresols; Disease Models, Animal; Dose-R | 2014 |
Memantine delayed N-methyl-D-aspartate -induced convulsions in neonatal rats.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Female; Male; Memantine; N-Methylaspartate; Rats; | 2015 |
Delayed preconditioning with NMDA receptor antagonists in a rat model of perinatal asphyxia.
Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Brain; Brain Ischemia; Disease Models, Animal; Dizoc | 2014 |
The uncompetitive N-methyl-D-aspartate antagonist memantine reduces binge-like eating, food-seeking behavior, and compulsive eating: role of the nucleus accumbens shell.
Topics: Animal Feed; Animals; Binge-Eating Disorder; Compulsive Behavior; Conditioning, Operant; Conflict, P | 2015 |
Treatment with UDP-glucose, GDNF, and memantine promotes SVZ and white matter self-repair by endogenous glial progenitor cells in neonatal rats with ischemic PVL.
Topics: Animals; Animals, Newborn; Brain; Brain Ischemia; Cell Hypoxia; Cell Proliferation; Cell Survival; C | 2015 |
MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Ag | 2015 |
A Combination Therapy of 17β-Estradiol and Memantine Is More Neuroprotective Than Monotherapies in an Organotypic Brain Slice Culture Model of Traumatic Brain Injury.
Topics: Animals; Brain Injuries; Disease Models, Animal; Drug Therapy, Combination; Estradiol; Estrogens; Hi | 2015 |
Protein dynamics associated with failed and rescued learning in the Ts65Dn mouse model of Down syndrome.
Topics: Animals; Disease Models, Animal; Down Syndrome; Learning; Memantine; Mice; Protein Subunits; Proteom | 2015 |
Neuroprotective effect of memantine on the retinal ganglion cells of APPswe/PS1ΔE9 mice and its immunomodulatory mechanisms.
Topics: Alzheimer Disease; Analysis of Variance; Animals; Disease Models, Animal; Electroretinography; Epend | 2015 |
NMDA Receptor Antagonist Attenuates Bleomycin-Induced Acute Lung Injury.
Topics: Acute Lung Injury; Amino Acids; Animals; Antibiotics, Antineoplastic; Bleomycin; Bronchoalveolar Lav | 2015 |
Memantine Attenuates Delayed Vasospasm after Experimental Subarachnoid Hemorrhage via Modulating Endothelial Nitric Oxide Synthase.
Topics: Animals; Blotting, Western; Disease Models, Animal; Endothelium, Vascular; Excitatory Amino Acid Ant | 2015 |
Self-Organizing Feature Maps Identify Proteins Critical to Learning in a Mouse Model of Down Syndrome.
Topics: Animals; Cluster Analysis; Disease Models, Animal; Down Syndrome; Gene Expression Regulation; Humans | 2015 |
Enhancing glutamatergic transmission during adolescence reverses early-life stress-induced deficits in the rewarding effects of cocaine in rats.
Topics: Administration, Intravenous; Aging; Amino Acid Transport System X-AG; Animals; Cocaine; Cocaine-Rela | 2015 |
CIH-induced neurocognitive impairments are associated with hippocampal Ca(2+) overload, apoptosis, and dephosphorylation of ERK1/2 and CREB that are mediated by overactivation of NMDARs.
Topics: Analysis of Variance; Animals; Apoptosis; Calcium; Cognition Disorders; CREB-Binding Protein; Diseas | 2015 |
Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats.
Topics: Administration, Cutaneous; Administration, Intravenous; Administration, Oral; Alzheimer Disease; Ani | 2016 |
Long-lasting effect of NMDA receptor antagonist memantine on ethanol-cue association and relapse.
Topics: Alcoholism; Animals; Conditioning, Psychological; Cues; Disease Models, Animal; Ethanol; Extinction, | 2015 |
Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments.
Topics: Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Drug S | 2016 |
Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil.
Topics: Aging; Alzheimer Disease; Animals; beta-Galactosidase; Cholinesterase Inhibitors; Cognition; Disease | 2015 |
Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Blotting, Western; Cognition Disorders; Dependovirus; | 2015 |
Elevated glucose and oligomeric β-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Case-Contr | 2016 |
NMDA receptor is involved in neuroinflammation in intracerebroventricular colchicine-injected rats.
Topics: Alzheimer Disease; Animals; Cell Adhesion; Colchicine; Cytotoxicity, Immunologic; Disease Models, An | 2016 |
Cognitive benefits of memantine in Alzheimer's 5XFAD model mice decline during advanced disease stages.
Topics: Alzheimer Disease; Animals; Cognition Disorders; Disease Models, Animal; Dopamine Agents; Memantine; | 2016 |
Effects of Memantine on Aminoglycoside-Induced Apoptosis of Spiral Ganglion Cells in Guinea Pigs.
Topics: Animals; Apoptosis; Blotting, Western; Cochlea; Disease Models, Animal; Gentamicins; Guinea Pigs; In | 2016 |
Memantine ameliorates autistic behavior, biochemistry & blood brain barrier impairments in rats.
Topics: Animals; Autistic Disorder; Blood-Brain Barrier; Brain; Disease Models, Animal; Excitatory Amino Aci | 2016 |
GluN3A promotes NMDA spiking by enhancing synaptic transmission in Huntington's disease models.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Glutamic Acid; Huntington Disease; Memantine; Mice | 2016 |
Memantine improves memory impairment and depressive-like behavior induced by amphetamine withdrawal in rats.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Antidepressive Agents; Central Nervous System S | 2016 |
Modeling and simulation of organophosphate-induced neurotoxicity: Prediction and validation by experimental studies.
Topics: Acetylcholinesterase; Animals; Brain Waves; Cholinesterase Reactivators; Computer Simulation; Diseas | 2016 |
Insulin potentiates the therapeutic effect of memantine against central STZ-induced spatial learning and memory deficit.
Topics: Animals; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 2016 |
The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Antiparkinson Agents; Cholinest | 2016 |
Memantine and Q-VD-OPh Treatments in Experimental Spinal Cord Injury: Combined Inhibition of Necrosis and Apoptosis.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Disease Models, Animal; Drug Therapy, Combinati | 2016 |
Microglia-Based Phenotypic Screening Identifies a Novel Inhibitor of Neuroinflammation Effective in Alzheimer's Disease Models.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognition; Disease Models, Animal; Donepez | 2016 |
Combining hypobaric hypoxia or hyperbaric oxygen postconditioning with memantine reduces neuroprotection in 7-day-old rat hypoxia-ischemia.
Topics: Animals; Animals, Newborn; Apoptosis; CA1 Region, Hippocampal; Disease Models, Animal; Hyperbaric Ox | 2016 |
Low dose of L-glutamic acid attenuated the neurological dysfunctions and excitotoxicity in bilateral common carotid artery occluded mice.
Topics: Animals; Brain; Brain Ischemia; Carotid Artery, Common; Disease Models, Animal; Dose-Response Relati | 2016 |
Differential regulation of GluA1 expression by ketamine and memantine.
Topics: Animals; Benzylamines; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; Excita | 2017 |
In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Drug Evaluation, Preclini | 2016 |
Blockade of the K
Topics: Alzheimer Disease; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Dendrites; Disease M | 2018 |
Effect of co-administration of memantine and sertraline on the antidepressant-like activity and brain-derived neurotrophic factor (BDNF) levels in the rat brain.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depressive Disorder; Disea | 2017 |
Glioprotection of Retinal Astrocytes After Intravitreal Administration of Memantine in the Mouse Optic Nerve Crush Model.
Topics: Animals; Astrocytes; Disease Models, Animal; Glial Fibrillary Acidic Protein; Intravitreal Injection | 2017 |
NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia.
Topics: Animals; Animals, Newborn; Antigens, Differentiation; Biomarkers; Brain; Disease Models, Animal; Exc | 2008 |
Memantine prevents the cognitive impairment induced by 3,4-methylenedioxymethamphetamine in rats.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Behavior, Animal; Central Nervous System Stimulants; Cogniti | 2008 |
Acute liver failure-induced death of rats is delayed or prevented by blocking NMDA receptors in brain.
Topics: Ammonia; Animals; Brain; Disease Models, Animal; Disease Progression; Dizocilpine Maleate; Excitator | 2008 |
Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Exploratory Beha | 2008 |
[Pathogenetic therapy of spasticity].
Topics: Adult; Aged; Animals; Cerebral Palsy; Child; Controlled Clinical Trials as Topic; Dantrolene; Diseas | 2008 |
The effect of N-methyl-D-aspartate receptor antagonist (memantine) on esophageal and gastric smooth muscle: functional investigation in a rat hydrocephalus model.
Topics: Animals; Disease Models, Animal; Esophagus; Hydrocephalus; Memantine; Muscle Contraction; Muscle, Sm | 2008 |
Memantine protects against secondary neuronal degeneration in lateral geniculate nucleus and superior colliculus after retinal damage in mice.
Topics: Animals; Cell Death; Disease Models, Animal; Drug Administration Schedule; Excitatory Amino Acid Ant | 2008 |
Augmentation of nitrite therapy in cerebral ischemia by NMDA receptor inhibition.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Drug Therapy, Combination; Excitatory Amino Acid An | 2009 |
Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Cyclopentanes; Diabetes Mellitus, Experime | 2009 |
Neuroprotective effect of memantine combined with topiramate in hypoxic-ischemic brain injury.
Topics: Animals; Animals, Newborn; Anticonvulsants; Apoptosis; Brain; Brain Infarction; Disease Models, Anim | 2009 |
Accuracy of hippocampal network activity is disrupted by neuroinflammation: rescue by memantine.
Topics: Animals; Brain Mapping; Cells, Cultured; Chronic Disease; Cytoskeletal Proteins; Disease Models, Ani | 2009 |
The combined effects of memantine and fluoxetine on an animal model of obsessive compulsive disorder.
Topics: Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Fluoxetine; Male; Memant | 2009 |
Protection of DFP-induced oxidative damage and neurodegeneration by antioxidants and NMDA receptor antagonist.
Topics: Animals; Antioxidants; Biomarkers; Brain; Cholinesterase Inhibitors; Cyclic N-Oxides; Disease Models | 2009 |
Increased expression of PAD2 after repeated intracerebroventricular infusions of soluble Abeta(25-35) in the Alzheimer's disease model rat brain: effect of memantine.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; CD11b Antigen; Disease Models, Animal; Hyd | 2009 |
Effect of memantine on the levels of neuropeptides and microglial cells in the brain regions of rats with neuropathic pain.
Topics: Analgesics; Animals; Brain; CD11 Antigens; Disease Models, Animal; Excitatory Amino Acid Antagonists | 2009 |
Effects of memantine on soluble Alphabeta(25-35)-induced changes in peptidergic and glial cells in Alzheimer's disease model rat brain regions.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomarkers; Brain; CD11 Antigens; Disease Models, | 2009 |
Model of methadone-induced hyperalgesia in rats and effect of memantine.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Hyperalgesia; Male; Memantine; Methadone; Rats; R | 2010 |
Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity.
Topics: Animals; Brain; Calcium Signaling; Cholinesterase Inhibitors; Dementia; Disease Models, Animal; Done | 2010 |
Memantine: "hypothesis testing" not "disease modifying" in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid; Animals; Antiparkinson Agents; Clinical Trials as Topic; Concept Formati | 2010 |
Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice.
Topics: Age Factors; Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antiparkinson Agents; Cogniti | 2010 |
Regulation of Kv2.1 phosphorylation in an animal model of anoxia.
Topics: Animals; Brain; Brain Chemistry; Cell Survival; Disease Models, Animal; Excitatory Amino Acid Antago | 2010 |
Folic Acid potentiates the effect of memantine on spatial learning and neuronal protection in an Alzheimer's disease transgenic model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Avoidance Learnin | 2010 |
Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.
Topics: Animals; Brain; Brain-Derived Neurotrophic Factor; Cholinergic Fibers; Chromosomes, Mammalian; Disea | 2011 |
Intracisternal administration of NR2 antagonists attenuates facial formalin-induced nociceptive behavior in rats.
Topics: Animals; Behavior, Animal; Cisterna Magna; Disease Models, Animal; Excitatory Amino Acid Antagonists | 2010 |
Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Antiparkinson | 2010 |
Memantine exacerbates myoclonic jerks in a rat model of posthypoxic myoclonus.
Topics: Animals; Cerebellum; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid | 2010 |
Effect of memantine on overactive detrusor in rats with spinal cord injury.
Topics: Animals; Disease Models, Animal; Female; Humans; Injections, Intraperitoneal; Male; Memantine; Rats; | 2010 |
The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine.
Topics: Aging; Amyloid beta-Peptides; Animals; Attention; Avoidance Learning; Cholinergic Fibers; Dementia; | 2011 |
Memantine reduces consumption of highly palatable food in a rat model of binge eating.
Topics: Animals; Binge-Eating Disorder; Dietary Fats; Disease Models, Animal; Eating; Feeding Behavior; Huma | 2011 |
Profile: Nicholas Dodman. Can dogs behaving badly suggest a new way to treat OCD?
Topics: Animals; Behavior, Animal; Cadherins; Compulsive Behavior; Disease Models, Animal; Dog Diseases; Dog | 2010 |
Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Autoradiography; Biological Transport; Brain; B | 2011 |
Memantine reduces mania-like symptoms in animal models.
Topics: Action Potentials; Animals; Antimanic Agents; Bipolar Disorder; Disease Models, Animal; Dose-Respons | 2011 |
Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Avoidance Learning; Discrimination, Psyc | 2011 |
Synaptic plasticity deficits in an experimental model of rett syndrome: long-term potentiation saturation and its pharmacological reversal.
Topics: Animals; Blotting, Western; Brain; Disease Models, Animal; Dopamine Agents; Immunohistochemistry; Lo | 2011 |
Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Disease Models, Animal; Excit | 2011 |
An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury.
Topics: Animals; Brimonidine Tartrate; Cell Count; Disease Models, Animal; Hyperbaric Oxygenation; Immunohis | 2011 |
Memantine prevents aluminum-induced cognitive deficit in rats.
Topics: Aluminum; Analysis of Variance; Animals; Body Weight; Cognition Disorders; Disease Models, Animal; D | 2011 |
Calpain activation is involved in acute manganese neurotoxicity in the rat striatum in vivo.
Topics: Analysis of Variance; Animals; Calpain; Caspase 3; Cell Death; Corpus Striatum; Disease Models, Anim | 2012 |
Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3β decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model.
Topics: Animals; Conditioning, Classical; Disease Models, Animal; Enzyme Inhibitors; Glycogen Synthase Kinas | 2011 |
Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Down Syndrome; Electric Stimulation; Excitato | 2011 |
Cell proliferation in the hippocampus and in the heart is modified by exposure to repeated stress and treatment with memantine.
Topics: Aldosterone; Analysis of Variance; Animals; Body Weight; Bromodeoxyuridine; Cell Count; Cell Prolife | 2012 |
Effects of the uncompetitive NMDA receptor antagonist memantine on spatial memory in medial septal lesioned rats.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Male; | 2011 |
Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Drug Syner | 2012 |
Structure/function studies and the effects of memantine in monkeys with experimental glaucoma.
Topics: Animals; Axons; Case-Control Studies; Disease Models, Animal; Evoked Potentials, Visual; Excitatory | 2012 |
False recognition in a mouse model of Alzheimer's disease: rescue with sensory restriction and memantine.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Electric Stimula | 2012 |
Pretreatment with memantine prevents Alzheimer-like alterations induced by intrahippocampal okadaic acid administration in rats.
Topics: Alzheimer Disease; Animals; Carcinogens; Chromatography, High Pressure Liquid; Cyclin-Dependent Kina | 2012 |
The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome.
Topics: Animals; Autistic Disorder; Cell Adhesion; Cell Movement; Cells, Cultured; Cerebellum; Dendritic Spi | 2012 |
Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
Topics: Animals; Apoptosis; Cerebral Cortex; Coculture Techniques; Corpus Striatum; Disease Models, Animal; | 2012 |
Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease.
Topics: Aging; Animals; Cerebral Cortex; Disease Models, Animal; Disease Progression; Dose-Response Relation | 2012 |
Memantine and dizocilpine interactions with antinociceptive or discriminative stimulus effects of morphine in rats after acute or chronic treatment with morphine.
Topics: Analgesics, Opioid; Animals; Discrimination Learning; Disease Models, Animal; Dizocilpine Maleate; D | 2013 |
A study on neuroinflammation and NMDA receptor function in STZ (ICV) induced memory impaired rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cytokines; Disease Models, Animal; Dose-Res | 2013 |
Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice.
Topics: Amnesia; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Galantamine; Ma | 2012 |
The smallest stroke: occlusion of one penetrating vessel leads to infarction and a cognitive deficit.
Topics: Animals; Brain Infarction; Brain Mapping; Calcium; Cognition Disorders; Disease Models, Animal; Dizo | 2013 |
Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Cyclic AMP Response Element-Binding Pr | 2013 |
Piperine decreases pilocarpine-induced convulsions by GABAergic mechanisms.
Topics: Alkaloids; Amino Acids; Animals; Anticonvulsants; Antioxidants; Atropine; Benzodioxoles; Biogenic Mo | 2013 |
Effects of memantine and melatonin on signal transduction pathways vascular leakage and brain injury after focal cerebral ischemia in mice.
Topics: Analysis of Variance; Animals; Cerebral Cortex; Cerebral Infarction; Corpus Striatum; Disease Models | 2013 |
Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model.
Topics: Aging; Analysis of Variance; Animals; Antihypertensive Agents; Brimonidine Tartrate; Cell Survival; | 2002 |
The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals.
Topics: Animals; Ataxia; Behavior, Animal; Catalepsy; Diamines; Disease Models, Animal; Dizocilpine Maleate; | 2003 |
Neurochemical characteristics of the ventromedial hypothalamus in mediating the antiaversive effects of anxiolytics in different models of anxiety.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Anti- | 2003 |
Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome.
Topics: 5-Hydroxytryptophan; Animals; Body Temperature; Clorgyline; Disease Models, Animal; Dizocilpine Male | 2004 |
Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol.
Topics: Adrenergic beta-Agonists; Animals; Brain Ischemia; Cells, Cultured; Clenbuterol; Disease Models, Ani | 2004 |
The presence of the APP(swe) mutation in mice does not increase the vulnerability of cholinergic basal forebrain neurons to neuroinflammation.
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Choline O-Acetyltransfera | 2004 |
Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury.
Topics: Amines; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Cyclohexanols; Disease Models, Animal | 2004 |
Effect of memantine on the levels of glial cells, neuropeptides, and peptide-degrading enzymes in rat brain regions of ibotenic acid-treated alzheimer's disease model.
Topics: Alzheimer Disease; Animals; Blotting, Western; Brain; Disease Models, Animal; Dopamine Agents; Elect | 2004 |
Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures.
Topics: Administration, Oral; Animals; Cell Count; Chronic Disease; Disease Models, Animal; Electroretinogra | 2004 |
Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures.
Topics: Administration, Oral; Animals; Cell Count; Cell Survival; Disease Models, Animal; Excitatory Amino A | 2004 |
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Cognition; Di | 2005 |
19F and 1H MRI detection of amyloid beta plaques in vivo.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloidosis; | 2005 |
The effects of memantine on lipid peroxidation following closed-head trauma in rats.
Topics: Animals; Brain; Brain Injuries; Disease Models, Animal; Excitatory Amino Acid Antagonists; Head Inju | 2005 |
Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Cholinesterase Inh | 2006 |
Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement.
Topics: Animals; Cerebral Hemorrhage; Disease Models, Animal; Gene Expression Regulation; Hematoma; Male; Ma | 2006 |
Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; G | 2005 |
Evidence for the involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Arginine; Cyclic GMP; Depression; Disease Mode | 2006 |
Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma.
Topics: Animals; Atrophy; Cell Count; Cytoprotection; Disease Models, Animal; Excitatory Amino Acid Antagoni | 2006 |
Low doses of memantine disrupt memory in adult rats.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Brain Edema; Disease Models, Animal; Excitatory Am | 2006 |
Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits.
Topics: Animals; Brain Infarction; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amin | 2006 |
Cognitive dysfunction induced by sequential injection of amyloid-beta and ibotenate into the bilateral hippocampus; protection by memantine and MK-801.
Topics: Amyloid beta-Peptides; Animals; Disease Models, Animal; Dizocilpine Maleate; Excitatory Amino Acid A | 2006 |
Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease.
Topics: Animals; Apoptosis Regulatory Proteins; Calpain; Cell Death; Corpus Striatum; Disease Models, Animal | 2006 |
Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat.
Topics: Animals; Behavior, Animal; Cytoskeletal Proteins; Disease Models, Animal; Dose-Response Relationship | 2006 |
Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage.
Topics: Animals; Caspase 3; CD11b Antigen; Celecoxib; Cerebral Hemorrhage; Collagenases; Disease Models, Ani | 2007 |
NMDA receptor-mediated excitotoxicity contributes to the cerebral hypoxic injury of a rat model of posthypoxic myoclonus.
Topics: Animals; Brain Damage, Chronic; Cerebellum; Disease Models, Animal; Excitatory Amino Acid Antagonist | 2007 |
Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.
Topics: Animals; Axons; Cell Survival; Disease Models, Animal; Erythropoietin; Fluorescent Antibody Techniqu | 2007 |
Failure to improve the effect of thrombolysis by memantine in a rat embolic stroke model.
Topics: Animals; Disease Models, Animal; Fibrinolytic Agents; Male; Memantine; Rats; Rats, Wistar; Statistic | 2007 |
Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test.
Topics: Age Factors; Analysis of Variance; Animals; Behavior, Animal; Conditioning, Psychological; Disease M | 2008 |
Transient allodynia pain models in mice for early assessment of analgesic activity.
Topics: Adrenergic alpha-Antagonists; Amines; Amitriptyline; Analgesics; Animals; Clonidine; Cyclohexanecarb | 2008 |
Expression of N-methyl-d-aspartate receptor 1 in rats with chronic ocular hypertension.
Topics: Analysis of Variance; Animals; Cell Death; Disease Models, Animal; Excitatory Amino Acid Antagonists | 2007 |
Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain-Derived Neurotrophic Factor; Disease Models, A | 2008 |
Memantine acts as a cholinergic stimulant in the mouse hippocampus.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Central Nervous System Stimulants; Cholinergic Fib | 2007 |
Effects of memantine and MK-801 on ischemia in an experimental model of acute subdural hematoma.
Topics: Animals; Brain Edema; Brain Ischemia; Disease Models, Animal; Dizocilpine Maleate; Excitatory Amino | 2008 |
Glutamate-mediated neuroplasticity in an animal model of self-injurious behaviour.
Topics: Animals; Behavior, Animal; Biogenic Monoamines; Disease Models, Animal; Dizocilpine Maleate; Excitat | 2008 |
Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Axons; Behavior, Animal; Brain; Conditioning, Psychological; Disease Mod | 2008 |
The clinically tested N-methyl-D-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy.
Topics: Animals; Disease Models, Animal; Hyperalgesia; Male; Memantine; Rats; Rats, Sprague-Dawley; Receptor | 1995 |
Memantine, a noncompetitive NMDA receptor antagonist improves hyperammonemia-induced encephalopathy and acute hepatic encephalopathy in rats.
Topics: Ammonia; Animals; Body Water; Brain; Disease Models, Animal; Electroencephalography; Glutamic Acid; | 1997 |
Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia.
Topics: Animals; Cell Count; Chromatography, High Pressure Liquid; Disease Models, Animal; Excitatory Amino | 1998 |
Ethanol-reinforced behaviour in the rat: effects of uncompetitive NMDA receptor antagonist, memantine.
Topics: Alcohol Drinking; Alcoholism; Animals; Disease Models, Animal; Drinking; Eating; Ethanol; Excitatory | 1998 |
Memantine for prevention of spinal cord injury in a rabbit model.
Topics: Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Evoked Potentials, Motor; Excitatory | 1999 |
[Glutamate receptor agonists and alcohol dependence. Preclinical findings].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Chronic Disease; Disease Models, Animal; Human | 1999 |
Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat.
Topics: Animals; Animals, Newborn; Brain; Brain Ischemia; Cerebrovascular Disorders; Disease Models, Animal; | 1999 |
A word of caution in extrapolating the spinal cord protective effects of memantine obtained in a rabbit model under ketamine anesthesia.
Topics: Anesthetics, Dissociative; Animals; Blood-Brain Barrier; Body Temperature; Disease Models, Animal; E | 1999 |
[Neuroprotective effect of N-methyl-D-aspartate receptor antagonists in an experimental glaucoma model in the rat].
Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Glaucoma; M | 2000 |
[Neuroprotection. Bases and possibilities of a future clinical use].
Topics: Adrenergic alpha-Agonists; Animals; Apoptosis; Brimonidine Tartrate; Clinical Trials as Topic; Disea | 2001 |
The role of neurochemical mechanisms of ventromedial hypothalamus in various models of anxiety in rats.
Topics: Adrenergic Agents; Animals; Anxiety; Apomorphine; Avoidance Learning; Disease Models, Animal; Dopami | 2001 |
[Prospects for neuroprotective glaucoma therapy].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Apoptosis; | 2001 |